Ric Day

Professor of Clinical Pharmacology & Toxicology
Professor

Prof Day AM (MBBS, FRACP, MD) is internationally and nationally recognised for his research, leadership and advocacy in support of quality use of medicines (QUM). He has been deeply involved in Australia’s National Medicines Policy and the QUM component culminating in his Chairmanship of the Pharmaceutical Health and Rational Use of Medicines Committee (PHARM) for the Federal Government in 1999-2008. PHARM provided strategic advice about QUM and supported the creation of the National Prescribing Service (NPS MedicinesWise). This work has informed his approach to advocacy and health policy and interventions. His research focuses on QUM and methods of enhancing the safe use of medicines using eHealth systems and decision support tools He has published over 600 peer reviewed papers: NEJM (4), BMJ (8), Lancet (5), Arch Intern Med (3), PLoS Med (2), Ann Intern Med (1), PNAS (1), & J Am Med Inform Assoc (9), & leading rheumatology (Ann Rheum Dis (6)) and clinical pharmacology journals (Clin Pharmacol Ther (7) and Brit J Clin Pharmacol (38). He has been cited over 22,600 times. He has published > 30 papers on gout. He collaborates widely in his research. His current collaborations have lead to significant work investigating the potential of eHealth tools to increase medication safety but he has other significant areas of research. Day collaborates especially with Profs E. Coiera & J. Westbrook, A/Profs M. Baysari, B. Gallego and A. Dunn (Health Systems and eHealth and Medication Safety Research all at Macquarie University, Sydney) and Prof. C.Maher, J.Latimer, C.Lin & colleagues (George Institute and University of Sydney -Large RCTs in primary care in musculoskeletal conditions) and Professor Anthony Rodgers (George Institute for Global Health – innovative clinical trial research designs in musculoskeletal disorders). Rigorous evaluation of electronic medication systems including implementation, effectiveness in reducing medication errors, decision support and alerts and new types of errors have led to highly cited publications (>26 papers). Day’s 5 year NH&MRC Partnership Grant (1094708) investigating the potential of eHealth tools to assist patients with gout adhere to their medications, of generic importance for chronic illnesses, builds on this work. Day’s innovative work extending the patient populations that can take metformin safely and benefit from its life saving cardiac protective properties, for example in people with type II diabetes and chronic kidney disease (CKD), non-diabetic obese women, people with cardiac failure and people with hepatic function impairment has been enhanced by national collaborations and is highly cited (e.g Graham et al, Clin Pharmacokin 2011; cited > 400 times).

Prof Day is a committed undergraduate & post-graduate teacher & research mentor (two awards) focussing on Quality Use of Medicines (QUM) & translation of evidence into practice. In the last 5 years, Day’s Honours (5), Independent Learning Program medical students (10), PhDs (13), MSc (3), Advanced trainees (3) and Post-Docs (5) have made 97 presentations nationally & internationally.

Prof Day has received many awards, including Member of the Order of Australia AM, 2000 relating mostly to his focus upon QUM. He received the AMA Distinguished Service Award in 2009 and became an Inaugural Life Member of the NPS in 2011. Prof Day was also the first non-US President of the Drug Information Association (DIA). Further, Prof Day is a practicing Rheumatologist and Clinical Pharmacologist and is an active educator and contributor to national resources such as the Australian Medicines Handbook (he was an inaugural Director) and Therapeutic Guidelines. Prof Day’s involvement with the pharmaceutical enterprise is extensive. He has held several positions including member of Medicines Australia Code of Conduct Committee since 1995; President of the national association of pharmacologists and toxicologists, ASCEPT 1995, Director of Medical Benefits Fund Australia, now BUPA, in 1998-2002, Co-chair of Medication Safety Taskforce for the Australian Safety and Quality Council (2001-3), Chair NPS R&D committee (2008-10), Ministerial Appointee of the Australian Health Informatics Committee 2003-5, Co-chair of National Electronic Medication Management reference group for the National e-Health Transition Authority and currently, Chair of Medication Expert Advisory Committee to the NSW Ministry of Health, Member NSW Early Phase Clinical Trials Committee, Member NSW Chief Scientist’s Cannabis Expert Advisory Committee, Chair NSW Cannabis Prescribers Committee, all for NSW Ministry of Health and Chair Research Advisory Committee of the National Institute of Complementary Medicine (NICM) Research Committee, University of Western Sydney 2014-17. Prof Day’s knowledge of, and connections to, the pharmaceutical industry are enhanced by his role as the senior academic advisor for Australia’s leading post-graduate degree in Drug Development – Masters of Pharmaceutical Medicine program that he cofounded at UNSW in the Faculty of Medicine.

Publications

Journal articles
add
Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S, 2020, 'Better outcomes for patients with gout', INFLAMMOPHARMACOLOGY, http://dx.doi.org/10.1007/s10787-020-00694-7
2020
Buchbinder R; Bourne A; Latimer J; Harris I; Whittle SL; Richards B; Taylor WJ; Clavisi O; Green S; Hinman RS; March L; Day R; Ferreira ML; Billot L; Maher CG, 2020, 'Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network', Internal Medicine Journal, vol. 50, pp. 17 - 23, http://dx.doi.org/10.1111/imj.14191
2020
Baysari MT; Zheng WY; Tariq A; Heywood M; Scott G; Li L; Van Dort BA; Rathnayake K; Day R; Westbrook JI, 2020, 'An experimental investigation of the impact of alert frequency and relevance on alert dwell time', International Journal of Medical Informatics, vol. 133, http://dx.doi.org/10.1016/j.ijmedinf.2019.104027
2020
Abdel Shaheed C; Maher CG; Buchbinder R; Ng B; Enke O; Guzowski R; McLachlan AJ; Day RO; Richards B; Latimer J; Lin CWC, 2020, 'Efficacy and harms of orally, intramuscularly or intravenously administered glucocorticoids for sciatica: A systematic review and meta-analysis', European Journal of Pain (United Kingdom), vol. 24, pp. 518 - 535, http://dx.doi.org/10.1002/ejp.1505
2020
Smith FC; Stocker SL; Danta M; Carland JE; Kumar SS; Liu Z; Greenfield JR; Braithwaite HE; Cheng TS; Graham GG; Williams KM; Day RO, 2020, 'The safety and pharmacokinetics of metformin in patients with chronic liver disease', Alimentary Pharmacology and Therapeutics, vol. 51, pp. 565 - 575, http://dx.doi.org/10.1111/apt.15635
2020
Day RO; Coleshill MJ; Stocker SL; Nguyen AD; Robinson P; Aung E, 2020, 'Predictors of Success in Gout Treatment', The Journal of rheumatology, vol. 47, pp. 313 - 315, http://dx.doi.org/10.3899/jrheum.191150
2020
Lowenstein D; Zheng WY; Burke R; Kenny E; Sandhu A; Makeham M; Westbrook J; Day RO; Baysari MT, 2019, 'Do user preferences align with human factors assessment scores of drug–drug interaction alerts?', Health Informatics Journal, pp. 1460458219840210, http://dx.doi.org/10.1177/1460458219840210
2019
Abdel Shaheed C; Carland JE; Graham GG; Stocker SL; Smith G; Hicks M; Williams KM; Furlong T; Macdonald P; Greenfield JR; Smith FC; Chowdhury G; Day RO, 2019, 'Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysis', British Journal of Clinical Pharmacology, vol. 85, pp. 2772 - 2783, http://dx.doi.org/10.1111/bcp.14107
2019
Coleshill MJ; Aung E; Nguyen AD; Stocker SL; Baysari MT; Kamel B; Schulz M; McLachlan AJ; Day RO, 2019, 'Improving adherence to urate-lowering therapy in people living with gout', International Journal of Rheumatic Diseases, vol. 22, pp. 542 - 544, http://dx.doi.org/10.1111/1756-185X.13566
2019
Darley DR; Carlos L; Hennig S; Liu Z; Day R; Glanville AR, 2019, 'Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection', European Journal of Clinical Pharmacology, vol. 75, pp. 879 - 888, http://dx.doi.org/10.1007/s00228-019-02658-5
2019
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG, 2019, 'Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting', Clinical Microbiology and Infection, vol. 25, pp. 1286.e1 - 1286.e7, http://dx.doi.org/10.1016/j.cmi.2019.02.029
2019
Chaudhri K; Kearney M; Day RO; Rodgers A; Atkins E, 2019, 'Effect of dose administration AIDS on adherence to self-administered medications: A systematic review protocol', BMJ Open, vol. 9, pp. e030536, http://dx.doi.org/10.1136/bmjopen-2019-030536
2019
Tay E; Sotiriou A; Graham GG; Wilhelm K; Snowden L; Day RO, 2019, 'Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance', THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, vol. 9, http://dx.doi.org/10.1177/2045125319836889
2019
Chaudhri K; Kearney M; Di Tanna GL; Day RO; Rodgers A; Atkins ER, 2019, 'Does splitting a tablet obtain the accurate dose?: A systematic review protocol', Medicine, vol. 98, pp. e17189, http://dx.doi.org/10.1097/MD.0000000000017189
2019
Van Dort BA; Baysari MT; Carland JE; Stocker SL; Braithwaite HE; Fernon AR; Day RO, 2019, 'Education to improve vancomycin use - The perspectives of educators and education recipients.', Intern Med J, http://dx.doi.org/10.1111/imj.14408
2019
Day RO; Lau W; Stocker SL; Aung E; Coleshill MJ; Schulz M; Bechara J; Carland JE; Graham GG; Williams KM; McLachlan AJ, 2019, 'Management of gout in older people', Journal of Pharmacy Practice and Research, vol. 49, pp. 90 - 97, http://dx.doi.org/10.1002/jppr.1511
2019
Baysari MT; Zheng WY; Li L; Westbrook J; Day RO; Hilmer S; Van Dort BA; Hargreaves A; Kennedy P; Monaghan C; Doherty P; Draheim M; Nair L; Samson R, 2019, 'Optimising computerised decision support to transform medication safety and reduce prescriber burden: Study protocol for a mixed-methods evaluation of drug-drug interaction alerts', BMJ Open, vol. 9, pp. e026034, http://dx.doi.org/10.1136/bmjopen-2018-026034
2019
Li JW; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, vol. 1, pp. e220 - e228, http://dx.doi.org/10.1016/S2665-9913(19)30078-5
2019
Tay EMY; Preisz P; Day RO, 2019, 'Role and impact of brain computed tomography in the management of drug overdoses and guideline recommendations', EMA - Emergency Medicine Australasia, vol. 31, pp. 1053 - 1058, http://dx.doi.org/10.1111/1742-6723.13316
2019
Shingde RV; Graham GG; Reuter SE; Carland JE; Day RO; Stocker SL, 2019, 'Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function.', Ther Drug Monit, vol. 41, pp. 726 - 731, http://dx.doi.org/10.1097/FTD.0000000000000690
2019
Day RO; Cohen M; Coleshill MJ; Ghinea N; Lipworth W; Maher CG; Latimer J; Lin CWC; McLachlan AJ, 2019, 'Is it ethical to prescribe paracetamol for acute low back pain and osteoarthritis?', The Lancet Rheumatology, vol. 1, pp. e140 - e142, http://dx.doi.org/10.1016/S2665-9913(19)30041-4
2019
Milder TY; Stocker SL; Shaheed CA; McGrath-Cadell L; Samocha-Bonet D; Greenfield JR; Day RO, 2019, 'Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis', JOURNAL OF CLINICAL MEDICINE, vol. 8, http://dx.doi.org/10.3390/jcm8010045
2019
Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR, 2019, 'Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease', European Journal of Clinical Pharmacology, vol. 75, pp. 1481 - 1490, http://dx.doi.org/10.1007/s00228-019-02732-y
2019
Shingde RV; Graham GG; Reuter SE; Carland JE; Day RO; Stocker SL, 2019, 'Comparison of the Area under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients with Normal Renal Function', Therapeutic Drug Monitoring, vol. 41, pp. 726 - 731, http://dx.doi.org/10.1097/FTD.0000000000000690
2019
Kamel B; Williams KM; Graham GG; Norris RLG; Stocker SL; Carland JE; Pile KD; Day RO, 2019, 'Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121764
2019
Brett J; Anthony C; Day R, 2019, 'Off-label quetiapine prescribing in general hospital inpatients', Journal of Pharmacy Practice and Research
2019
Nguyen AD; Lind KE; Day RO; Georgiou A; Westbrook JI, 2019, 'A profile of health status and demographics of aged care facility residents with gout', Australasian Journal on Ageing, http://dx.doi.org/10.1111/ajag.12716
2019
Baysari M; Del Gigante J; Moran M; Lehnbom E; Day R, 2019, 'Mandatory Medication Indications in Electronic Systems a he Prescriber Perspective', Stud Health Technol Inform, vol. 265, pp. 95 - 100, http://dx.doi.org/10.3233/SHTI190145
2019
Ghinea N; Wiersma M; Kerridge I; Olver I; Pearson S; Day R; Liauw W; Lipworth W, 2019, '“Some sort of fantasy land”: A qualitative investigation of appropriate prescribing in cancer care', Journal of Evaluation in Clinical Practice, http://dx.doi.org/10.1111/jep.13278
2019
Leopoldino AO; MacHado GC; Ferreira PH; Pinheiro MB; Day R; McLachlan AJ; Hunter DJ; Ferreira ML, 2019, 'Paracetamol versus placebo for knee and hip osteoarthritis', Cochrane Database of Systematic Reviews, vol. 2019, http://dx.doi.org/10.1002/14651858.CD013273
2019
Nguyen AD; Frensham LJ; Baysari MT; Carland JE; Day RO, 2018, 'Patients' use of mobile health applications: What general practitioners think', Family Practice, vol. 36, pp. 214 - 218, http://dx.doi.org/10.1093/fampra/cmy052
2018
Counsell AB; Nguyen AD; Baysari MT; Kannangara DRW; McLachlan AJ; Day RO, 2018, 'Exploring current and potential roles of Australian community pharmacists in gout management: A qualitative study', BMC Family Practice, vol. 19, http://dx.doi.org/10.1186/s12875-018-0744-3
2018
Kumar SS; McManus H; Radovich T; Greenfield JR; Viardot A; Williams KM; Cronin P; Day RO, 2018, 'Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM)', European Journal of Clinical Pharmacology, vol. 74, pp. 1327 - 1332, http://dx.doi.org/10.1007/s00228-018-2506-5
2018
Zheng WY; Richardson LC; Li L; Day RO; Westbrook JI; Baysari MT, 2018, 'Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis', European Journal of Clinical Pharmacology, vol. 74, pp. 15 - 27, http://dx.doi.org/10.1007/s00228-017-2357-5
2018
Meslin SMM; Zheng WY; Day RO; Tay EMY; Baysari MT, 2018, 'Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation', Applied Clinical Informatics, vol. 9, pp. 849 - 855, http://dx.doi.org/10.1055/s-0038-1676039
2018
Maali Y; Perez-Concha O; Coiera E; Roffe D; Day RO; Gallego B, 2018, 'Predicting 7-day, 30-day and 60-day all-cause unplanned readmission: A case study of a Sydney hospital', BMC Medical Informatics and Decision Making, vol. 18, http://dx.doi.org/10.1186/s12911-017-0580-8
2018
Chan JOS; Baysari MT; Carland JE; Sandaradura I; Moran M; Day RO, 2018, 'Barriers and facilitators of appropriate vancomycin use: prescribing context is key', European Journal of Clinical Pharmacology, vol. 74, pp. 1523 - 1529, http://dx.doi.org/10.1007/s00228-018-2525-2
2018
Imani S; Buscher H; Day R; Gentili S; Jones GRD; Marriott D; Norris R; Sandaradura I, 2018, 'An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy', European Journal of Clinical Microbiology and Infectious Diseases, vol. 37, pp. 2171 - 2175, http://dx.doi.org/10.1007/s10096-018-3357-9
2018
Ma CKK; Danta M; Day R; Ma DDF, 2018, 'Dealing with the spiralling price of medicines: issues and solutions', Internal Medicine Journal, vol. 48, pp. 16 - 24, http://dx.doi.org/10.1111/imj.13652
2018
Lin CWC; Li Q; Williams CM; Maher CG; Day RO; Hancock MJ; Latimer J; Mclachlan AJ; Jan S, 2018, 'The economic burden of guideline-recommended first line care for acute low back pain', European Spine Journal, vol. 27, pp. 109 - 116, http://dx.doi.org/10.1007/s00586-016-4781-0
2018
Nguyen AD; Frensham LJ; Wong MXC; Meslin SMM; Martin P; Lau AYS; Baysari MT; Day RO, 2018, 'Mhealth app patient testing and review of educational materials designed for self-management of gout patients: Descriptive qualitative studies', JMIR mHealth and uHealth, vol. 6, http://dx.doi.org/10.2196/mhealth.9811
2018
Graham GG; Stocker SL; Kannangara DRW; Day RO, 2018, 'Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout', Current Rheumatology Reports, vol. 20, http://dx.doi.org/10.1007/s11926-018-0760-2
2018
Carland JE; Smith FC; Day RO, 2018, 'Lactic Acidosis, Metformin Use, and Dose-Response Association', JAMA Internal Medicine, vol. 178, pp. 1428 - 1429, http://dx.doi.org/10.1001/jamainternmed.2018.4448
2018
Baysari MT; Lowenstein D; Zheng WY; Day RO, 2018, 'Reliability, ease of use and usefulness of I-MeDeSA for evaluating drug-drug interaction alerts in an Australian context', BMC Medical Informatics and Decision Making, vol. 18, http://dx.doi.org/10.1186/s12911-018-0666-y
2018
Indraratna PL; Virk S; Gurram D; Day RO, 2018, 'Use of colchicine in pregnancy: A systematic review and meta-analysis', Rheumatology (United Kingdom), vol. 57, pp. 382 - 387, http://dx.doi.org/10.1093/rheumatology/kex353
2018
Baysari MT; Tariq A; Day RO; Westbrook JI, 2017, 'Alert override as a habitual behavior - A new perspective on a persistent problem', Journal of the American Medical Informatics Association, vol. 24, pp. 409 - 412, http://dx.doi.org/10.1093/jamia/ocw072
2017
Ramanathan SA; Hibbert PD; Maher CG; Day RO; Hindmarsh DM; Hooper TD; Hannaford NA; Runciman WB, 2017, 'CareTrack', Spine, vol. 42, pp. E802 - E809, http://dx.doi.org/10.1097/BRS.0000000000001972
2017
Baysari MT; Gigante JD; Moran M; Sandaradura I; Li L; Richardson KL; Sandhu A; Lehnbom EC; Westbrook JI; Day RO, 2017, 'Redesign of computerized decision support to improve antimicrobial prescribing', Applied Clinical Informatics, vol. 8, pp. 949 - 963, http://dx.doi.org/10.4338/ACI2017040069
2017
Day RO, 2017, 'Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration (vol 68, pg 990, 2016)', AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 69, pp. 870 - 870, http://dx.doi.org/10.1053/j.ajkd.2017.03.016
2017
Braithwaite J; Westbrook J; Coiera E; Runciman WB; Day R; Hillman K; Herkes J, 2017, 'A systems science perspective on the capacity for change in public hospitals', Israel Journal of Health Policy Research, vol. 6, http://dx.doi.org/10.1186/s13584-017-0143-6
2017
Machado GC; Maher CG; Ferreira PH; Day RO; Pinheiro MB; Ferreira ML, 2017, 'Non-steroidal anti-inflammatory drugs for spinal pain: A systematic review and meta-analysis', Annals of the Rheumatic Diseases, vol. 76, pp. 1269 - 1278, http://dx.doi.org/10.1136/annrheumdis-2016-210597
2017
Mathieson S; Maher CG; McLachlan AJ; Latimer J; Koes BW; Hancock MJ; Harris I; Day RO; Billot L; Pik J; Jan S; Lin CWC, 2017, 'Trial of pregabalin for acute and chronic sciatica', New England Journal of Medicine, vol. 376, pp. 1111 - 1120, http://dx.doi.org/10.1056/NEJMoa1614292
2017
Jones G; Panova E; Day R, 2017, 'Guideline development for the management of gout: Role of combination therapy with a focus on lesinurad', Drug Design, Development and Therapy, vol. 11, pp. 3077 - 3081, http://dx.doi.org/10.2147/DDDT.S97959
2017
Walter SR; Day RO; Gallego B; Westbrook JI, 2017, 'The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia', British Journal of Clinical Pharmacology, vol. 83, pp. 416 - 426, http://dx.doi.org/10.1111/bcp.13124
2017
Lyell D; Magrabi F; Raban MZ; Pont LG; Baysari MT; Day RO; Coiera E, 2017, 'Automation bias in electronic prescribing', BMC Medical Informatics and Decision Making, vol. 17, http://dx.doi.org/10.1186/s12911-017-0425-5
2017
Leung S; Zheng WY; Sandhu A; Day R; Li L; Baysari M, 2017, 'Feedback and training to improve use of an electronic prescribing system: A randomised controlled trial', Studies in Health Technology and Informatics, vol. 239, pp. 63 - 69, http://dx.doi.org/10.3233/978-1-61499-783-2-63
2017
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO, 2017, 'Individualising the dose of allopurinol in patients with gout', British Journal of Clinical Pharmacology, vol. 83, pp. 2015 - 2026, http://dx.doi.org/10.1111/bcp.13307
2017
2017, 'Erratum: Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum].', Drug Des Devel Ther, vol. 11, pp. 3589 - 3590, http://dx.doi.org/10.2147/DDDT.S158965
2017
Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, vol. 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745
2017
Shaheed CA; Mathieson S; Day RO; Maher CG; McLACHLAN AJ; McLACHLAN H; Lin CWC, 2017, 'What is the evidence for opioid analgesia for low back pain?', Medicine Today, vol. 18, pp. 24 - 27
2017
Kamel B; Graham GG; Williams KM; Pile KD; Day RO, 2017, 'Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat', Clinical Pharmacokinetics, vol. 56, pp. 459 - 475, http://dx.doi.org/10.1007/s40262-016-0466-4
2017
Wiles LK; Hibbert PD; Stephens JH; Coiera E; Westbrook J; Braithwaite J; Day RO; Hillman KM; Runciman WB, 2017, 'STANDING Collaboration: A study protocol for developing clinical standards', BMJ Open, vol. 7, http://dx.doi.org/10.1136/bmjopen-2016-014048
2017
Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2017, 'A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function', European Journal of Clinical Pharmacology, vol. 73, pp. 981 - 990, http://dx.doi.org/10.1007/s00228-017-2251-1
2017
Day RO, 2017, 'Introduction to the Special Section: Phase I Clinical Trials', Therapeutic Innovation and Regulatory Science, vol. 51, pp. 274 - 275, http://dx.doi.org/10.1177/2168479017706513
2017
Day RO; Snowden L; McLachlan AJ, 2017, 'Life-threatening drug interactions: what the physician needs to know', Internal Medicine Journal, vol. 47, pp. 501 - 512, http://dx.doi.org/10.1111/imj.13404
2017
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M, 2017, 'Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries', The Lancet, vol. 389, pp. 1268 - 1272, http://dx.doi.org/10.1016/S0140-6736(16)32051-7
2017
Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KJ; Portek I; Williams KM; Westbrook JI, 2017, 'Effectiveness of an electronic patient-centred self-management tool for gout sufferers: A cluster randomised controlled trail protocol', BMJ Open, vol. 7, http://dx.doi.org/10.1136/bmjopen-2017-017281
2017
day RO, 2016, 'Ganciclovir - Hypoglycaemia', WHO SIGNAL, pp. 15 - 18
2016
Day R; Hung SI; Chung WH, 2016, 'Allopurinol dose relative to renal function and risk of hypersensitivity reactions', Annals of the Rheumatic Diseases, vol. 75, pp. e21, http://dx.doi.org/10.1136/annrheumdis-2015-209109
2016
Santucci W; Day RO; Baysari MT, 2016, 'Evaluation of hospital-wide computerised decision support in an intensive care unit: An observational study', Anaesthesia and Intensive Care, vol. 44, pp. 507 - 512
2016
Ní Chróinín D; Neto HM; Xiao D; Sandhu A; Brazel C; Farnham N; Perram J; Roach TS; Sutherland E; Day R; Beveridge A, 2016, 'Potentially inappropriate medications (PIMs) in older hospital in-patients: Prevalence, contribution to hospital admission and documentation of rationale for continuation', Australasian Journal on Ageing, vol. 35, pp. 262 - 265, http://dx.doi.org/10.1111/ajag.12312
2016
Day RO; Snowden L, 2016, 'Where to find information about drugs', Australian Prescriber, vol. 39, pp. 88 - 95, http://dx.doi.org/10.18773/austprescr.2016.023
2016
Tay EM; Graham RI; Day RO, 2016, 'Severe GHB withdrawal delirium managed with dexmedetomidine', The Medical journal of Australia, vol. 205, pp. 251 - 252, http://dx.doi.org/10.5694/mja16.00269
2016
De Lautour H; Taylor WJ; Adebajo A; Alten R; Burgos-Vargas R; Chapman P; Cimmino MA; Da Rocha Castelar Pinheiro G; Day R; Harrold LR; Helliwell P; Janssen M; Kerr G; Kavanaugh A; Khanna D; Khanna PP; Lin C; Louthrenoo W; McCarthy G; Vazquez-Mellado J; Mikuls TR; Neogi T; Ogdie A; Perez-Ruiz F; Schlesinger N; Ralph Schumacher H; Scirè CA; Singh JA; Sivera F; Slot O; Stamp LK; Tausche AK; Terkeltaub R; Uhlig T; Van De Laar M; White D; Yamanaka H; Zeng X; Dalbeth N, 2016, 'Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises', Arthritis Care and Research, vol. 68, pp. 667 - 672, http://dx.doi.org/10.1002/acr.22741
2016
Day RO; Kamel B; Kannangara DRW; Williams KM; Graham GG, 2016, 'Xanthine oxidoreductase and its inhibitors: Relevance for gout', Clinical Science, vol. 130, pp. 2167 - 2180, http://dx.doi.org/10.1042/CS20160010
2016
Mathieson S; Billot L; Maher CG; McLachlan AJ; Latimer J; Koes BW; Hancock MJ; Harris I; Day RO; Pik J; Jan S; Lin CWC, 2016, 'PRECISE - pregabalin in addition to usual care: Statistical analysis plan', Trials, vol. 17, http://dx.doi.org/10.1186/s13063-016-1174-y
2016
Baysari MT; Lehnbom EC; Li L; Hargreaves A; Day RO; Westbrook JI, 2016, 'The effectiveness of information technology to improve antimicrobial prescribing in hospitals: A systematic review and meta-analysis', International Journal of Medical Informatics, vol. 92, pp. 15 - 34, http://dx.doi.org/10.1016/j.ijmedinf.2016.04.008
2016
Kannangara DRW; Graham GG; Williams KM; Day RO, 2016, 'Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine', Clinical Rheumatology, vol. 35, pp. 2375 - 2376, http://dx.doi.org/10.1007/s10067-015-3165-x
2016
Moon J; Kumar SS; Graham GG; Baysari MT; Williams KM; Chen W; Viardot A; Greenfield JR; Day RO, 2016, 'Trends in metformin utilisation and dose appropriateness in Australia', European Journal of Clinical Pharmacology, vol. 72, pp. 1489 - 1496, http://dx.doi.org/10.1007/s00228-016-2117-y
2016
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Smith FC; Kumar SS; Furlong TJ; Gangaram SV; Greenfield JR; Stocker SL; Graham GG; Williams KM; Day RO, 2016, 'Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration', American Journal of Kidney Diseases, vol. 68, pp. 990 - 992, http://dx.doi.org/10.1053/j.ajkd.2016.08.017
2016
Martin JH; Henry D; Gray J; Day R; Bochner F; Ferro A; Pirmohamed M; Mörike K; Schwab M, 2016, 'Achieving the World Health Organization's vision for clinical pharmacology', British journal of clinical pharmacology, vol. 81, pp. 223 - 227, http://dx.doi.org/10.1111/bcp.12803
2016
Baysari MT; Jackson N; Ramasamy S; Santiago P; Xiong J; Westbrook J; Omari A; Day RO, 2016, 'Exploring sub-optimal use of an electronic risk assessment tool for venous thromboembolism', Applied Ergonomics, vol. 55, pp. 63 - 69, http://dx.doi.org/10.1016/j.apergo.2016.01.003
2016
Richardson LC; Lehnbom EC; Baysari MT; Walter SR; Day RO; Westbrook JI, 2016, 'A time and motion study of junior doctor work patterns on the weekend: a potential contributor to the weekend effect?', Internal Medicine Journal, vol. 46, pp. 819 - 825, http://dx.doi.org/10.1111/imj.13120
2016
Lin CWC; McLachlan AJ; Latimer J; Day RO; Billot L; Koes BW; Maher CG, 2016, 'OPAL: A randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol', BMJ Open, vol. 6, http://dx.doi.org/10.1136/bmjopen-2016-011278
2016
Shaheed CA; Maher CG; Williams KA; Day R; McLachlan AJ, 2016, 'Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain a systematic review and meta-analysis', JAMA Internal Medicine, vol. 176, pp. 958 - 968, http://dx.doi.org/10.1001/jamainternmed.2016.1251
2016
Westbrook JI; Li L; Raban MZ; Baysari MT; Mumford V; Prgomet M; Georgiou A; Kim T; Lake R; McCullagh C; Dalla-Pozza L; Karnon J; O'Brien TA; Ambler G; Day R; Cowell CT; Gazarian M; Worthington R; Lehmann CU; White L; Barbaric D; Gardo A; Kelly M; Kennedy P, 2016, 'Stepped-wedge cluster randomised controlled trial to assess the effectiveness of an electronic medication management system to reduce medication errors, adverse drug events and average length of stay at two paediatric hospitals: A study protocol', BMJ Open, vol. 6, http://dx.doi.org/10.1136/bmjopen-2016-011811
2016
Stamp LK; Day RO; Yun J, 2016, 'Allopurinol hypersensitivity: Investigating the cause and minimizing the risk', Nature Reviews Rheumatology, vol. 12, pp. 235 - 242, http://dx.doi.org/10.1038/nrrheum.2015.132
2016
Vaccher S; Kannangara DRW; Baysari MT; Reath J; Zwar N; Williams KM; Day RO, 2016, 'Barriers to care in gout: From prescriber to patient', Journal of Rheumatology, vol. 43, pp. 144 - 149, http://dx.doi.org/10.3899/jrheum.150607
2016
Kannangara DRW; Phipps-Green AJ; Dalbeth N; Stamp LK; Williams KM; Graham GG; Day RO; Merriman TR, 2016, 'Hyperuricaemia: Contributions of urate transporter ABCG2 and the fractional renal clearance of urate', Annals of the Rheumatic Diseases, vol. 75, pp. 1363 - 1366, http://dx.doi.org/10.1136/annrheumdis-2015-208111
2016
Rasheed H; McKinney C; Stamp LK; Dalbeth N; Topless RK; Day R; Kannangara D; Williams K; Smith M; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; Lu L; Stahl EA; Choi HK; So A; Merriman TR, 2016, 'The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and polynesian sample sets', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0147939
2016
Nguyen AD; Baysari MT; Kannangara DRW; Tariq A; Lau AYS; Westbrook JI; Day RO, 2016, 'Mobile applications to enhance self-management of gout', International Journal of Medical Informatics, vol. 94, pp. 67 - 74, http://dx.doi.org/10.1016/j.ijmedinf.2016.06.021
2016
Butterfield RJ; Barratt MJ; Ezard N; Day RO, 2016, 'Drug checking to improve monitoring of new psychoactive substances in Australia Drug checking may need to play a part in future public health interventions', MEDICAL JOURNAL OF AUSTRALIA, vol. 204, pp. 144 - +, http://dx.doi.org/10.5694/mja15.01058
2016
Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO, 2015, 'The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus', British Journal of Clinical Pharmacology, vol. 79, pp. 617 - 623, http://dx.doi.org/10.1111/bcp.12525
2015
Hmar RC; Kannangara DRW; Ramasamy SN; Baysari MT; Williams KM; Day RO, 2015, 'Understanding and improving the use of allopurinol in a teaching hospital', Internal Medicine Journal, vol. 45, pp. 383 - 390, http://dx.doi.org/10.1111/imj.12701
2015
Wiley J; Westbrook M; Long J; Greenfield JR; Day RO; Braithwaite J, 2015, 'Multidisciplinary diabetes team care: The experiences of young adults with Type 1 diabetes', Health Expectations, vol. 18, pp. 1783 - 1796, http://dx.doi.org/10.1111/hex.12170
2015
Missiakos O; Baysari MT; Day RO, 2015, 'Identifying effective computerized strategies to prevent drug-drug interactions in hospital: A user-centered approach', International Journal of Medical Informatics, vol. 84, pp. 595 - 600, http://dx.doi.org/10.1016/j.ijmedinf.2015.04.001
2015
McKinney C; Stamp LK; Dalbeth N; Topless RK; Day RO; Kannangara DRW; Williams KM; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; So A; Merriman TR, 2015, 'Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout', Arthritis Research and Therapy, vol. 17, http://dx.doi.org/10.1186/s13075-015-0802-3
2015
Gallego B; Walter SR; Day RO; Dunn AG; Sivaraman V; Shah N; Longhurst CA; Coiera E, 2015, 'Bringing cohort studies to the bedside: Framework for a 'green button' to support clinical decision-making', Journal of Comparative Effectiveness Research, vol. 4, pp. 191 - 197, http://dx.doi.org/10.2217/cer.15.12
2015
Westbrook JI; Li L; Lehnbom EC; Baysari MT; Braithwaite J; Burke R; Conn C; Day RO, 2015, 'What are incident reports telling us? A comparative study at two Australian hospitals of medication errors identified at audit, detected by staff and reported to an incident system', International Journal for Quality in Health Care, vol. 27, pp. 1 - 9, http://dx.doi.org/10.1093/intqhc/mzu098
2015
Fransen M; Agaliotis M; Nairn L; Votrubec M; Bridgett L; Su S; Jan S; March L; Edmonds J; Norton R; Woodward M; Day R; Buckland-Wright C; Bridges-Webb C; Heritier S; Jones G; Sambrook P; Speechly C; Vignon E; Jovanovic G; Jeram S; Dowd M; Champion M; Grealy S; Watson D; Vrataric A; Johnson C; White R; O'Connell P; Milwraith F; Kennedy D; Faulkes C; Bulton O; Johnson K, 2015, 'Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens', Annals of the Rheumatic Diseases, vol. 74, pp. 851 - 858, http://dx.doi.org/10.1136/annrheumdis-2013-203954
2015
Cai X; Perez-Concha O; Coiera E; Martin-Sanchez F; Day R; Roffe D; Gallego B, 2015, 'Real-time Prediction of Mortality, Readmission and Length of Stay Using Electronic Health Record Data', Journal of the American Medical Informatics Association, vol. 23, pp. 553 - 561, http://dx.doi.org/10.1093/jamia/ocv110
2015
Machado GC; Maher CG; Ferreira PH; Pinheiro MB; Lin CWC; Day RO; McLachlan AJ; Ferreira ML, 2015, 'Efficacy and safety of paracetamol for spinal pain and osteoarthritis: Systematic review and meta-analysis of randomised placebo controlled trials', BMJ (Online), vol. 350, http://dx.doi.org/10.1136/bmj.h1225
2015
Day RO, 2015, 'Prednisone for cardiac failure in patients with hypertension', Journal of Rheumatology, vol. 42, pp. 739 - 740, http://dx.doi.org/10.3899/jrheum.150276
2015
Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MHH; Williams KM; Tian YC; Juan KC; Wu YJJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI, 2015, 'Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin', Annals of the Rheumatic Diseases, vol. 74, pp. 2157 - 2164, http://dx.doi.org/10.1136/annrheumdis-2014-205577
2015
Merriman TR; Stamp LK; Dalbeth N; Topless R; Day R; Kannangara D; Williams K; Janssen M; Jansen T; Joosten LA; Radstake T; Riches PL; Tausche A-K; Liote F; So A; McKinney C, 2015, 'Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout', ARTHRITIS & RHEUMATOLOGY, vol. 67, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370860204715&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Lin CWC; Day RO; Harris I; Maher CG; McLachlan A, 2015, 'Comparative efficacy trials with no placebo group cannot determine efficacy', BMJ (Online), vol. 350, http://dx.doi.org/10.1136/bmj.h3292
2015
Day R; Lipworth W; Ghinea N, 2015, 'The Ethics Around Drug Labels and Generic Medicines', Therapeutic Innovation and Regulatory Science, vol. 49, pp. 348 - 351, http://dx.doi.org/10.1177/2168479015577867
2015
Diasinos N; Baysari M; Kumar S; Day RO, 2015, 'Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?', Internal Medicine Journal, vol. 45, pp. 55 - 62, http://dx.doi.org/10.1111/imj.12627
2015
Wang LW; He EYJ; Ghosh D; Day RO; Jones GRD; Subbiah RN; Holloway CJ, 2015, 'Severe carbon monoxide poisoning from waterpipe smoking: A public health concern', Medical Journal of Australia, vol. 202, pp. 446 - 448, http://dx.doi.org/10.5694/mja14.01264
2015
Ghosh D; McGann PM; Furlong TJ; Day RO, 2015, 'Febuxostat-associated rhabdomyolysis in chronic renal failure', Medical Journal of Australia, vol. 203, pp. 107 - 108, http://dx.doi.org/10.5694/mja14.01404
2015
Westbrook JI; Gospodarevskaya E; Li L; Richardson KL; Roffe D; Heywood M; Day RO; Graves N, 2015, 'Cost-effectiveness analysis of a hospital electronic medication management system', Journal of the American Medical Informatics Association, vol. 22, pp. 784 - 793, http://dx.doi.org/10.1093/jamia/ocu014
2015
Baysari MT; Adams K; Lehnbom EC; Westbrook JI; Day RO, 2014, 'iPad use at the bedside: A tool for engaging patients in care processes during ward rounds?', Internal Medicine Journal, vol. 44, pp. 986 - 990, http://dx.doi.org/10.1111/imj.12518
2014
Inam S; Lipworth W; Kerridge I; Day R, 2014, 'A review of strategies to improve rational prescribing in asthma', Journal of Pharmacy Practice and Research, vol. 44, pp. 195 - 200, http://dx.doi.org/10.1002/jppr.1034
2014
Kannangara DRW; Graham GG; Williams KM; Day RO, 2014, 'Hypouricemic effects of prednisone and allopurinol: An uneven playing field?', Canadian Journal of Cardiology, vol. 30, pp. 376.e1, http://dx.doi.org/10.1016/j.cjca.2013.04.015
2014
Wiley J; Westbrook M; Long J; Greenfield JR; Day RO; Braithwaite J, 2014, 'Diabetes Education: the Experiences of Young Adults with Type 1 Diabetes', Diabetes Therapy, vol. 5, pp. 299 - 321, http://dx.doi.org/10.1007/s13300-014-0056-0
2014
Lehnbom EC; Adams K; Day RO; Westbrook JI; Baysari MT, 2014, 'IPad use during ward rounds: An observational study', Studies in Health Technology and Informatics, vol. 204, pp. 67 - 73, http://dx.doi.org/10.3233/978-1-61499-427-5-67
2014
Baysari MT; Westbrook JI; Richardson K; Day RO, 2014, 'Optimising computerised alerts within electronic medication management systems: A synthesis of four years of research', Studies in Health Technology and Informatics, vol. 204, pp. 1 - 6, http://dx.doi.org/10.3233/978-1-61499-427-5-1
2014
Ghosh D; Williams KM; Graham GG; Nair P; Buscher H; Day RO, 2014, 'Multiple episodes of aspirin overdose in an individual patient: A case report', Journal of Medical Case Reports, vol. 8, pp. 1 - 5, http://dx.doi.org/10.1186/1752-1947-8-374
2014
Perera V; Bies RR; Mo G; Dolton MJ; Carr VJ; McLachlan AJ; Day RO; Polasek TM; Forrest A, 2014, 'Optimal sampling of antipsychotic medicines: A pharmacometric approach for clinical practice', British Journal of Clinical Pharmacology, vol. 78, pp. 800 - 814, http://dx.doi.org/10.1111/bcp.12410
2014
Lipworth W; Doran E; Kerridge I; Day R, 2014, 'Challenges to pharmaceutical policymaking: Lessons from Australia's national medicines policy', Australian Health Review, vol. 38, pp. 160 - 168, http://dx.doi.org/10.1071/AH13240
2014
Williams CM; Maher CG; Latimer J; McLachlan AJ; Hancock MJ; Day RO; Lin C-WC, 2014, 'Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial', The Lancet, vol. 384, pp. 1586 - 1596, http://dx.doi.org/10.1016/S0140-6736(14)60805-9
2014
Fransen M; Day RO, 2014, 'Response to A. G. Helg's comments on the LEGS study', Annals of the Rheumatic Diseases, vol. 73, http://dx.doi.org/10.1136/annrheumdis-2014-205569
2014
Ghinea N; Lipworth W; Kerridge I; Little M; Day RO, 2014, 'Ethics & evidence in medical debates: The case of recombinant activated factor VII', Hastings Center Report, vol. 44, pp. 38 - 45, http://dx.doi.org/10.1002/hast.287
2014
Wiley J; Westbrook M; Greenfield JR; Day RO; Braithwaite J, 2014, 'Shared decision-making: The perspectives of young adults with type I diabetes mellitus', Patient Preference and Adherence, vol. 8, pp. 423 - 435, http://dx.doi.org/10.2147/PPA.S57707
2014
Perera V; Dolton MJ; McLachlan AJ; Carr VJ; Day RO, 2014, 'Pharmacometrics: An underused resource in Australian clinical research', Medical Journal of Australia, vol. 200, pp. 82 - 83, http://dx.doi.org/10.5694/mja13.10663
2014
Rasheed H; Topless R; Day R; Kannangara D; Williams K; Bradbury L; Brown M; Hill C; Lester S; Rischmueller M; Smith M; Andres M; Bardin T; Doherty M; Janssen M; Jansen T; Joosten L; Perez-Ruiz F; Radstake T; Riches PL; Roddy E; Tausche A-K; Stamp LK; Dalbeth N; Liote F; So A; McKinney C; Merriman TR, 2014, 'Association of the Toll-like Receptor 4 (TLR4) Gene with Gout.', ARTHRITIS & RHEUMATOLOGY, vol. 66, pp. S1294 - S1295, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344384906196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2014
Lipworth WL; Kerridge IH; Day RO, 2013, 'Formulating an ethics agenda for drug development, regulation, and utilization', Therapeutic Innovation & Regulatory Science, vol. 47, pp. 46 - 49, http://dx.doi.org/10.1177/2168479012469949
2013
Wiley J; Westbrook M; Long J; Greenfield JR; Day RO; Braithwaite J, 2013, 'Multidisciplinary diabetes team care: The experiences of young adults with Type 1 diabetes', Health Expectations, http://dx.doi.org/10.1111/hex.12170
2013
Day R; Lee H; Graham G; Williams K, 2013, 'Benzbromarone: Availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt on benzbromarone)', New Zealand Medical Journal, vol. 126, pp. 124 - 126
2013
Missiakos O; Baysari MT; Day RO, 2013, 'Identifying effective strategies to prevent drug-drug interactions in hospital: A user-centered approach', 49th Annual Human Factors and Ergonomics Society of Australia Conference 2013, HFESA 2013
2013
Day R, 2013, 'Off-label prescribing', Australian Prescriber, vol. 36, pp. 182 - 183, http://dx.doi.org/10.18773/austprescr.2013.075
2013
Carmichael SJ; Day RO; Tett S, 2013, 'A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus', Internal Medicine Journal, vol. 43, pp. 547 - 553, http://dx.doi.org/10.1111/imj.12100
2013
Graham GG; Davies MJ; Day RO; Mohamudally A; Scott KF, 2013, 'The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.', Inflammopharmacology, vol. 21, pp. 201 - 232, http://dx.doi.org/10.1007/s10787-013-0172-x
2013
Kannangara DRW; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO, 2013, 'An audit of a therapeutic drug monitoring service for allopurinol therapy', Therapeutic Drug Monitoring, vol. 35, pp. 863 - 866, http://dx.doi.org/10.1097/FTD.0b013e318299920a
2013
Day RO; Graham GG, 2013, 'Republished research: Non-steroidal anti-inflammatory drugs (NSAIDs)', British Journal of Sports Medicine, vol. 47, pp. 1127, http://dx.doi.org/10.1136/bjsports-2013-f3195rep
2013
Wong C; Kumar SS; Graham GG; Begg EJ; Chin P; Brett J; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Comparing dose prediction software used to manage gentamicin dosing', Internal Medicine Journal, vol. 43, pp. 519 - 525, http://dx.doi.org/10.1111/imj.12067
2013
Lee M-H; Stocker S; Williams KM; Day RO, 2013, 'HLA-B*5801 should be used to screen for risk of Stevens-Johnson Syndrome (SJS) in family members of Han-Chinese patients commencing allopurinol therapy', Journal of Rheumatology, vol. 40, pp. 96 - 97, http://dx.doi.org/10.3899/jrheum.120803
2013
Gallego B; Runciman WB; Perez-Concha O; Liaw ST; Day RO; Dunn AG; Coiera E, 2013, 'The management of severe hypertension in Australian general practice', BMC Health Services Research, vol. 13, http://dx.doi.org/10.1186/1472-6963-13-414
2013
Westbrook JI; Baysari MT; Li L; Burke R; Richardson KL; Day RO, 2013, 'The safety of electronic prescribing: Manifestations, mechanisms, and rates of system-related errors associated with two commercial systems in hospitals', Journal of the American Medical Informatics Association, vol. 20, pp. 1159 - 1167, http://dx.doi.org/10.1136/amiajnl-2013-001745
2013
Brett J; Chong O; Graham GG; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Antifungal Use and Therapeutic Monitoring of Plasma Concentrations of Itraconazole in Heart and Lung Transplantation Patients.', Therapeutic Drug Monitoring, vol. 35, pp. 133 - 136, http://dx.doi.org/10.1097/FTD.0b013e318275fe69
2013
Duong JK; Kumar SS; Carl m kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO, 2013, 'Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes: Simulation of doses according to renal function', Clinical Pharmacokinetics, vol. 52, pp. 373 - 384, http://dx.doi.org/10.1007/s40262-013-0046-9
2013
Arabadzhiyska PN; Baysari MT; Walter S; Day RO; Westbrook JI, 2013, 'Shedding light on junior doctors' work practices after hours', Internal Medicine Journal, vol. 43, pp. 1321 - 1326, http://dx.doi.org/10.1111/imj.12223
2013
Tea CK; Baysari MT; Day RO, 2013, 'Compliance with antibiotic prescribing policy: Perspectives of policymakers and prescribers', Australian Journal of Pharmacy, vol. 94, pp. 74 - 77
2013
Lee P; Day RO; Greenfield JR; Ho KK, 2013, 'Formoterol, a highly selective beta 2-selective agonist, increases energy expenditure and fat utilisation in men', International journal of obesity, vol. 37, pp. 593 - 597, http://dx.doi.org/10.1038/ijo.2012.90
2013
Harris IA; Day RO, 2013, 'PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial', Trials, vol. 14, pp. 213, http://dx.doi.org/10.1186/1745-6215-14-213
2013
Ghinea N; Lipworth W; Little M; Kerridge I; Day R, 2013, 'Overcoming Entrenched Disagreements: the Case of Misoprostol for Post-Partum Haemorrhage', Developing World Bioethics, vol. 15, pp. n/a - n/a, http://dx.doi.org/10.1111/dewb.12040
2013
Lewis JRR; Lipworth WL; Kerridge IH; Day RO, 2013, 'The economic evaluation of personalised oncology medicines: Ethical challenges', Medical Journal of Australia, vol. 199, pp. 471 - 473, http://dx.doi.org/10.5694/mja13.10046
2013
Day RO; Graham GG, 2013, 'Non-steroidal anti-inflammatory drugs (NSAIDs)', BMJ, vol. 346, pp. Article No. f3195, http://dx.doi.org/10.1136/bmj.f3195
2013
Williams CM; Maher CG; Latimer J; McLachlan AJ; Hancock MJ; Day RO; Billot L; Lin CWC, 2013, 'PACE - the first placebo controlled trial of paracetamol for acute low back pain: Statistical analysis plan', Trials, vol. 14, http://dx.doi.org/10.1186/1745-6215-14-248
2013
Ramasamy SN; Korb-Wells CS; Kannangara DRW; Smith MWH; Wang N; Roberts DM; Graham GG; Williams KM; Day RO, 2013, 'Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012', Drug Safety, vol. 36, pp. 953 - 980, http://dx.doi.org/10.1007/s40264-013-0084-0
2013
Baysari MT; Oliver K; Egan B; Li L; Richardson K; Sandaradura I; Westbrook JI; Day RO, 2013, 'Audit and feedback of antibiotic use', Applied Clinical Informatics, vol. 4, pp. 583 - 595, http://dx.doi.org/10.4338/ACI-2013-08-RA-0063
2013
Baysari M; Day R; Teo CK, 2013, 'Understanding compliance to an antibiotic prescribing policy: Perspectives of policymakers and prescribers', Journal of Pharmacy Practice and Research, vol. 43, pp. 32 - 36, http://dx.doi.org/10.1002/j.2055-2335.2013.tb00212.x
2013
Runciman WB; Hunt TD; Hannaford NA; Hibbert PD; Westbrook JI; Coiera EW; Day RO; Hindmarsh DM; McGlynn EA; Braithwaite J, 2012, 'CareTrack: assessing the appropriateness of health care delivery in Australia REPLY', MEDICAL JOURNAL OF AUSTRALIA, vol. 197, pp. 549 - 550, http://dx.doi.org/10.5694/mja12.11210
2012
Day RO; Kannangara DRW; Hayes JM; Furlong TJ, 2012, 'Successful use of allopurinol in a patient on dialysis', BMJ Case Reports, vol. 2012, pp. 1 - 3, http://dx.doi.org/10.1136/bcr.02.2012.5814
2012
Lipworth WL; Kerridge IH; Little M; Day RO, 2012, 'Evidence and desperation in off-label prescribing: Recombinant factor VIIa', British Medical Journal: International, vol. 344, pp. d7926, http://dx.doi.org/10.1136/bmj.d7926
2012
Baysari MT; Tang T; Brett J; Day RO, 2012, 'Implementation of revised aminoglycoside guidelines: Australian hospitals 'left in the lurch'', Journal of Pharmacy Practice and Research, vol. 42, pp. 178 - 179, http://dx.doi.org/10.1002/j.2055-2335.2012.tb00163.x
2012
Dunn AG; Braithwaite J; Gallego Luxan B; Day RO; Runciman W; Coiera E, 2012, 'Nation-scale adoption of new medicines by doctors: An application of the Bass diffusion model', BMC Health Services Research, vol. 12, pp. 248 - 257, http://dx.doi.org/10.1186/1472-6963-12-248
2012
Kannangara D; Roberts DM; Furlong TJ; Graham GG; Williams K; Day RO, 2012, 'Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease', British Journal of Clinical Pharmacology, vol. 73, pp. 828 - 829, http://dx.doi.org/10.1111/j.1365-2125.2011.04147.x
2012
Hunt T; Ramanathan S; Hannaford N; Hibbert P; Braithwaite J; Coiera E; Day RO; Westbrook J; Runciman W, 2012, 'CareTrack Australia: assessing the appropriateness of adult healthcare: Protocol for a retrospective medical record review', BMJ Open, vol. 2, pp. 665, http://dx.doi.org/10.1136/bmjopen-2011-000665
2012
Runciman WB; Coiera E; Day RO; Hannaford NA; Hibbert PD; Hunt T; Westbrook JI; Braithwaite J, 2012, 'Towards the delivery appropriate healthcare in Australia', Medical Journal of Australia, vol. 197, pp. 78 - 81, http://dx.doi.org/10.5694/mja12.10799
2012
Baysari MT; Westbrook J; Day RO, 2012, 'Understanding doctors perceptions of their prescribing competency and the value they ascribe to an electronic prescribing system', Studies in Health Technology and Informatics,Volume 178: Health Informatics: Building a Healthcare Future Through Trusted Information, vol. 178, pp. 1 - 6, http://dx.doi.org/10.3233/978-1-61499-078-9-1
2012
Stocker S; Mclachlan AJ; Savic RM; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'The pharmacokinetics of oxypurinol in people with gout', British Journal of Clinical Pharacology, vol. 74, pp. 477 - 489, http://dx.doi.org/10.1111/j.1365-2125.2012.04207.x
2012
Lipworth WL; Kerridge IH; Day RO, 2012, 'Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda', Medical Journal of Australia, vol. 196, pp. 374 - 375, http://dx.doi.org/10.5694/mja12.10152
2012
Lipworth WL; Ho K; Kerridge IH; Day RO, 2012, 'Drug policy at the margins: The case of growth hormone replacement for adults with severe growth hormone deficiency', Medical Journal of Australia, vol. 197, pp. 204 - 205, http://dx.doi.org/10.5694/mja11.11572
2012
Runciman W; Hunt T; Hannaford N; Hibbert P; Westbrook J; Coiera E; Hindmarsh D; Day RO; Mcglynn EA; Braithwaite J, 2012, 'CareTrack: Assessing the appropriateness of health care delivery in Australia', Medical Journal of Australia, vol. 197, pp. 100 - 105, http://dx.doi.org/10.5694/mja12.10510
2012
Lipworth WL; Kerridge IH; Day RO, 2012, 'Wrong questions, wrong answers? Are we getting the drugs we need?', Clinical Pharmacology and Therapeutics, vol. 91, pp. 367 - 369, http://dx.doi.org/10.1038/clpt.2011.335
2012
Baysari MT; Day RO; Westbrook J, 2012, 'Consistency or efficiency? A dilemma for designers', Journal of the American Medical Informatics Association, vol. 19, pp. 1119 - 1120, http://dx.doi.org/10.1136/amiajnl-2012-001254
2012
Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'Metformin therapy in patients with chronic kidney disease', Diabetes Obesity and Metabolism, vol. 14, pp. 963 - 965, http://dx.doi.org/10.1111/j.1463-1326.2012.01617.x
2012
Dunn AG; Day RO; Mandl K; Coiera E, 2012, 'Learning from Hackers: Open-Source Clinical Trials', Science Translational Medicine, vol. 4, pp. 132cm5, http://dx.doi.org/10.1126/scitranslmed.3003682
2012
Dunn AG; Bourgeois F; Murthy S; Mandl K; Day RO; Coiera E, 2012, 'The role and impact of research agendas on the comparative effectiveness research amongst anti-hyperlipidemics', Clinical Pharmacology and Therapeutics, vol. 91, pp. 685 - 691, http://dx.doi.org/10.1038/clpt.2011.279
2012
Ghinea N; Lipworth WL; Kerridge IH; Day RO, 2012, 'No evidence or no alternative? Taking responsibility for off-label prescribing', Internal Medicine Journal, vol. 42, pp. 247 - 251, http://dx.doi.org/10.1111/j.1445-5994.2012.02713.x
2012
Westbrook J; Reckmann M; Li L; Runciman W; Burke R; Lo C; Baysari MT; Braithwaite J; Day RO, 2012, 'Effects of two commercial electronic prescribing systems on prescribing error rates in hospital inpatients: a before and after study', PLOS Medicine, vol. 9, pp. e1001164, http://dx.doi.org/10.1371/journal.pmed.1001164
2012
Lee M-H; Stocker S; Anderson JM; Phillips EJ; Nolan DL; Williams KM; Graham GG; Sullivan JR; Day RO, 2012, 'Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status?', Internal Medicine Journal, vol. 42, pp. 411 - 416, http://dx.doi.org/10.1111/j.1445-5994.2011.02567.x
2012
Kannangara DRW; Ramasamy SN; Indraratna P; Stocker S; Graham GG; Jones G; Portek I; Williams KM; Day RO, 2012, 'Fractional clearance of urate: Validation of measurement in spot urine samples in healthy subjects and gouty patients', Arthritis Research and Therapy, vol. 14, pp. R189 - R197, http://dx.doi.org/10.1186/ar4020
2012
Day RO; Kannangara DRW; Hayes JM; Furlong TJ, 2012, 'Successful use of allopurinol in a patient on dialysis.', BMJ case reports, vol. 2012
2012
Baysari MT; Reckmann M; Li L; Day RO; Westbrook J, 2012, 'Failure to utilize functions of an electronic prescribing system and the subsequent generation of 'technically preventable' computerized alerts', Journal of the American Medical Informatics Association, vol. 19, pp. 1003 - 1010, http://dx.doi.org/10.1136/amiajnl-2011-000730
2012
Lee P; Kengne A; Greenfield JR; Day RO; Chalmers J; Ho KK, 2011, 'Metabolic sequelae of beta-blocker theraphy: weighing in on the obesity epidemic?', International journal of obesity, vol. 35, pp. 1395 - 1403, http://dx.doi.org/10.1038/ijo.2010.284
2011
Wang N; Lipworth WL; Ritchie JE; Williams K; Day RO, 2011, 'Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines', Internal Medicine Journal, vol. 41, pp. 314 - 320, http://dx.doi.org/10.1111/j.1445-5994.2010.02239.x
2011
Milder T; Lipworth W; Ritchie J; Williams K; Day R, 2011, 'WHAT DRIVES OSTEOARTHRITIS PATIENTS TO USE OR NOT USE NSAIDS, PARACETAMOL AND COMPLEMENTARY MEDICATIONS?', INTERNAL MEDICINE JOURNAL, vol. 41, pp. 23 - 24, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290489900080&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Roberts DM; Smith MA; McMullan B; Sevastos J; Day RO, 2011, 'Acute kidney injury due to crystalluria following acute valacycolvir overdose', Kidney International, vol. 79, pp. 574 - 575, http://dx.doi.org/10.1038/ki.2010.496
2011
Brett J; Beresford R; Sevastos J; Day RO, 2011, 'Neem Extract Poisoning as a Cause of Renal Tubular Acidosis', Journal of Clinical Toxicology, vol. 1, pp. 112, http://dx.doi.org/10.4172/2161-0495.1000112
2011
Harvey K; Day RO; Campbell W; Lipworth WL, 2011, 'Saving money on the PBS: Ranibizumab or Bevacizumab for Neovascular Macular Degeneration?', Medical Journal of Australia, vol. 194, pp. 567 - 568
2011
Stocker SL; Graham GG; McLachlan AJ; Williams K; Day RO, 2011, 'Pharmacokinetic and Pharmacodynamic interaction between allopurinol and probenecid in patients with gout', Journal of Rheumatology, vol. 38, pp. 904 - 910, http://dx.doi.org/10.3899/jrheum.101160
2011
Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, vol. 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514
2011
Roberts DM; Smith MA; Gopalakrishnan M; Whittaker G; Day RO, 2011, 'Extreme y-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis', Annals of Emergency Medicine, vol. 58, pp. 83 - 85, http://dx.doi.org/10.1016/j.annemergmed.2011.01.017
2011
Inam S; Lipworth WL; Kerridge IH; Day RO, 2011, 'Rethinking the discordance between guidelines and practice in the treatment of rheumatoid arthritis: a failure of practice or failure of evidence?', Medical Journal of Australia, vol. 195, pp. 446 - 447
2011
Roberts DM; Smith MA; Ritson R; Day RO, 2011, 'Death and morbidity from supratherapeutic dosing of colchicine: 3 cases over 2 weeks', Medical Journal of Australia, vol. 194, pp. 612 - 613
2011
Bell AJ; Mcd taylor D; Holdgate A; MacBean C; Huynh T; Thom O; Augello M; Millar R; Day RE; Williams AG; Ritchie P; Pasco J, 2011, 'Procedural sedation practices in Australian Emergency Departments', Emergency Medicine Australasia, vol. 23, pp. 458 - 465, http://dx.doi.org/10.1111/j.1742-6723.2011.01418.x
2011
Henneicke H; Herrmann M; Kalak R; Brennan-Speranza TC; Heinevetter U; Bertollo N; Day RE; Huscher D; Buttgereit F; Dunstan CR; Seibel MJ; Zhou H, 2011, 'Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism', Bone, vol. 49, pp. 733 - 742, http://dx.doi.org/10.1016/j.bone.2011.06.013
2011
Graham GG; Punt J; Manit A; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup L; Carl m kirkpatrick CM; Ray J; Timmins P; Williams KM, 2011, 'Clinical pharmacokinetics of metforim', Clinical Pharmacokinetics, vol. 50, pp. 81 - 98, http://dx.doi.org/10.2165/11534750-000000000-00000
2011
Bombardier C; Laine L; Day RO; Hawkey CJ; Hochberg MC; Schnitzer TJ, 2011, 'Rofecoxib and clinically significant gastrointestinal events', American Journal of the Medical Sciences, vol. 342, pp. 438 - 439, http://dx.doi.org/10.1097/MAJ.0b013e31822f3ff4
2011
Mcd taylor D; Bell AJ; Holdgate A; MacBean C; Huynh T; Thom O; Augello M; Millar R; Day RE; Williams AG; Ritchie P; Pasco J, 2011, 'Risk factors for sedation-related events during procedural sedation in the emergency departmentemm_1419 466..473', Emergency Medicine Australasia, vol. 23, pp. 466 - 473, http://dx.doi.org/10.1111/j.1742-6723.2011.01419.x
2011
Lipworth WL; Kerridge IH; Brett J; Day RO, 2011, 'How clinical and resaerch failures lead to suboptimal prescribing: the example of chronic gout', British Medical Journal, vol. 343, pp. 1 - 3, http://dx.doi.org/10.1136/bmj.d7459
2011
Carney SL; Gazarian M; Denholm JT; Reith DM; Penhall RK; Jenkins CR; Wilhelm KA; Komesaroff P; Osborn MM; Day RO, 2011, 'What's in a name? Brand name confusion and generic medicines', Medical Journal of Australia, vol. 195, pp. 650 - 651
2011
Day RO; Roffe D; Richardson K; Baysari MT; Brennan NJ; Beveridge AH; Melocco T; Ainge J; Westbrook J, 2011, 'Implementing electronic medication management at an Australian teaching hospital', Medical Journal of Australia, vol. 195, pp. 498 - 502, http://dx.doi.org/10.5694/mja11.10451
2011
Sklar P; Ripke S; Scott LJ; Andreassen OA; Cichon S; Craddock N; Edenberg HJ; Nurnberger JI; Rietschel M; Blackwood D; Corvin A; Flickinger M; Guan W; Mattingsdal M; McQuillan A; Kwan P; Wienker TF; Daly MJ; Dudbridge F; Holmans PA; Lin D; Burmeister M; Greenwood TA; Hamshere ML; Muglia P; Smith EN; Zandi PP; Nievergelt CM; McKinney R; Shilling PD; Schork NJ; Bloss CS; Foroud T; Koller DL; Gershon ES; Liu C; Badner JA; Scheftner WA; Lawson WB; Nwulia EA; Hipolito M; Coryell W; Rice J; Byerley W; McMahon FJ; Schulze TG; Berrettini W; Lohoff FW; Potash JB; Mahon AP; McInnis MG; Zollner S; Zhang P; Craig DW; Szelinger S; Barrett TB; Breuer R; Meier S; Strohmaier J; Witt SH; Tozzi F; Farmer A; McGuffin P; Strauss J; Xu W; Kennedy JL; Vincent JB; Matthews K; Day R; Ferreira MA; O'Dushlaine C; Perlis R; Raychaudhuri S; Ruderfer D; Hyoun PL; Smoller JW; Li J; Absher D; Thompson RC; Meng FG; Schatzberg A; Bunney WE; Barchas JD; Jones EG; Watson SJ; Myers RM; Akil H; Boehnke M; Chambert K; Moran J; Scolnick EM; Djurovic S; Melle I; Morken G; Gill M; Morris D; Quinn E; Muhleisen TW; Degenhardt FA; Mattheisen M; Schumacher J; Maier W; Steffens M; Propping P; Nothen MM; Anjorin A; Bass N; Gurling H; Kandaswamy R; Lawrence J; McGhee K; McIntosh A; McLean AW; Muir WJ; Pickard BS; Breen G; St Clair D; Caesar S; Gordon-Smith K; Jones L; Fraser C; Green EK; Grozeva D; Jones IR; Kirov G; Moskvina V; Nikolov I; O'Donovan MC; Owens MJ; Collier DA; Elkin A; Williamson R; Young AH; Ferrier IN; Stefansson K; Stefansson H; Porgeirsson P; Steinberg S; Gustafsson O; Bergen SE; Nimgaonkar V; Hultman C; Landen M; Lichtenstein P; Sullivan P; Schalling M; Osby U; Backlund L; Frisen L; Langstrom N; Jamain S; Leboyer M; Etain B; Bellivier F; Petursson H; Sigurgosson E; Muller-Mysok B; Lucae S; Schwarz M; Schofield PR; Martin N; Montgomery GW; Lathrop M; Oskarsson H; Bauer M; Wright A; Mitchell PB; Hautzinger M; Reif A; Kelsoe JR; Purcell SM, 2011, 'Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4', Nature Genetics, vol. 43, pp. 977 - 985, http://dx.doi.org/10.1038/ng.943
2011
Ramasamy S; Kannangara D; Indraratna P; Stocker S; Jones G; Graham G; Williams K; Day R, 2011, 'ESTABLISHING THE USEFULNESS OF A SPOT URINE COLLECTION IN CALCULATING THE FRACTIONAL RENAL CLEARANCE OF URATE (FCU)', INTERNAL MEDICINE JOURNAL, vol. 41, pp. 31 - 31, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290489900106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Ng DY; Stocker SL; Graham GG; Williams KM; Day RO, 2011, 'Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers', European Journal of Clinical Pharmacology, vol. 67, pp. 709 - 713, http://dx.doi.org/10.1007/s00228-010-0963-6
2011
Kannangara D; Datta I; Indraratna P; Stocker S; Portek I; Graham G; Williams K; Day R, 2011, 'INDIVIDUALISING ALLOPURINOL THERAPY IN GOUT', INTERNAL MEDICINE JOURNAL, vol. 41, pp. 30 - 30, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290489900103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2011
Carney SL; Gazarian M; Denholm JT; Reith DM; Penhall RK; Jenkins CR; Wilhelm KA; Komesaroff PA; Osborn MM; Day RO, 2011, 'What's in a name? Brand name confusion and generic medicines', Medical Journal of Australia, vol. 195, pp. 650 - 651, http://dx.doi.org/10.5694/mja10.10968
2011
Lipworth WL; Wodak A; Haber P; Day RO, 2011, 'Why is Disulfiram not on the PBS?', Medical Journal of Australia, vol. 195, pp. 371 - 372, http://dx.doi.org/10.5694/mja11.10708
2011
Smith MWH; Roberts DM; Ritson SM; Day RO, 2011, 'Death and morbidity from supratherapeutic dosing of colchicine', Medical Journal of Australia, vol. 194, pp. 612 - 613
2011
Inam S; Lipworth WL; Kerridge IH; Day RO, 2011, 'Rethinking the discordance between guidelines and practice in rheumatoid arthritis treatment', Medical Journal of Australia, vol. 195, pp. 446 - 447, http://dx.doi.org/10.5694/mja11.10068
2011
Greenfield JR; Graham GG; Day RO, 2011, 'The Use of Metformin in Diabetic Patients with Renal Impairment', Geriatric Medicine in General Practice, vol. 8, pp. 26 - 29, http://search.informit.com.au/documentSummary;dn=109054076198131;res=IELHEA
2011
Milder T; Williams K; Ritchie JE; Lipworth WL; Day RO, 2011, 'Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: Engagement with information and perceptions of risk', Age and Ageing, vol. 40, pp. 254 - 259, http://dx.doi.org/10.1093/ageing/afq160
2011
Lipworth WL; Kerridge I; Brett J; Day R, 2011, 'How clinical and research failures lead to suboptimal prescribing: the example of chronic gout.', British Medical Journal, vol. 343, pp. d7459, http://dx.doi.org/10.1136/bmj.d7459
2011
Day RO; Lipworth WL; Kerridge IH, 2011, 'Death of the ‘Blockbuster’ and ‘Pivotal’ Clinical Trial: Rethinking the Drug Development Process.', Journal of Pharmacy Practice and Research, vol. 41, pp. 94 - 95, http://dx.doi.org/10.1002/j.2055-2335.2011.tb00671.x
2011
Day R; Pomerantz P, 2011, 'Thomas W. Teal In Memoriam', DRUG INFORMATION JOURNAL, vol. 45, pp. II - II
2011
Baysari MT; Westbrook J; Richardson K; Day RO, 2011, 'The influence of computerized decision support on prescribing during ward rounds: are the decision-makers targeted?', Journal of the American Medical Informatics Association, vol. 18, pp. 754 - 759, http://dx.doi.org/10.1136/amiajnl-2011-000135
2011
Baysari MT; Westbrook J; Braithwaite J; Day R, 2011, 'The Role of Computerized Decision Support in Reducing Errors in Selecting Medicines for Prescription: Narrative Review', Drug Safety, vol. 34, pp. 289 - 298, http://dx.doi.org/10.2165/11588200-000000000-00000
2011
Westbrook JI; Woods A; Rob MI; Dunsmuir WTM; Day RO, 2010, 'Association of interruptions with an increased risk and severity of medication administration errors', Archives of Internal Medicine, vol. 170, pp. 683 - 690, http://dx.doi.org/10.1001/archinternmed.2010.65
2010
Graham GG; Day RO; Graudins A; Mohamudally A, 2010, 'FDA proposals to limit the hepatoxicity of paracetamol (acetaminophen). Are they resonable?', Inflammopharmacology, vol. 18, pp. 47 - 55, http://dx.doi.org/10.1007/s10787-010-0036-6
2010
Lu CY; Lu VH; Goldberg I; Day RO, 2010, 'Towards integrated care: Australia's new model of care for patients with glaucoma', Medical Journal of Australia, vol. 193, pp. 200 - 201
2010
Indraratna P; Stocker SL; Williams KM; Graham GG; Jones G; Day RO, 2010, 'A proposal for identifying the low renal uric acid clearance phenotype', Arthritis Research and Therapy, vol. 12, pp. 149 - 151, http://dx.doi.org/10.1186/ar3191
2010
Graham GG; Day RO; Graudins A; Mohamudally A, 2010, 'Erratum: FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): Are they reasonable? (Inflammopharmacol DOI: 10.1007/s10787-010-0036-6)', Inflammopharmacology, vol. 18, pp. 57, http://dx.doi.org/10.1007/s10787-010-0039-3
2010
Wallace H; Graham GG; Williams K; Day RO, 2010, 'A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine', Pain Medicine, vol. 11, pp. 951 - 965, http://dx.doi.org/10.1111/j.1526-4637.2010.00867.x
2010
Day RO; Liauw WS; Tozer L; McElduff P; Beckett RJ; Williams K, 2010, 'A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenpausal women', BMC Research Notes, vol. 3, pp. 1 - 8, http://dx.doi.org/10.1186/1756-0500-3-180
2010
Standfield L; Norris S; Elliott L; Riordan J; Hall S; Day RO; Nash P; Thirunavukkarasu K; Robertson J; Palmer T, 2010, 'Relationship between rheumatoid arthritis disease severity, health related utility and resource use in Australian rheumatoid arthritis patients', Clinical Therapeutics, vol. 32, pp. 1329 - 1342
2010
Williams CM; Latimer J; Maher C; McLachlan AJ; Cooper C; Hancock M; Day RO; McAuley J; Lin C, 2010, 'PACE-the first placebo controlled trail of paracetamol for acute low back pain:design of a randomised controlled trial', BMC Musculoskeletal Disorders, vol. 11, pp. 1 - 11, http://dx.doi.org/10.1186/1471-2474-11-169
2010
Standfield L; Norris S; Harvey C; Elliot L; Riordan J; Hall S; Day R; Nash P; Thirunavukkarasu K; Robertson J; Palmer T, 2010, 'Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in australian patients: A cross-sectional, multicenter study', Clinical Therapeutics, vol. 32, pp. 1329 - 1342, http://dx.doi.org/10.1016/j.clinthera.2010.07.006
2010
Carter SM; Samuel GN; Kerridge I; Day R; Ankeny RA; Jordens CFC; Komesaroff P, 2010, 'Beyond rhetoric in debates about the Ethics of marketing prescription medicines to consumers: The importance of Vulnerability in people, situations, and relationships', AJOB Primary Research, vol. 1, pp. 11 - 21, http://dx.doi.org/10.1080/21507716.2010.482871
2010
Magrabi F; Li S; Day RO; Coiera E, 2010, 'Errors and electronic prescribing: A controlled laboratory study to examine task complexity and interruption effects', American Medical Informatics Association Annual Symposium Proceedings, vol. 17, pp. 575 - 583, http://dx.doi.org/10.1136/jamia.2009.001719
2010
Stocker S; Franklin M; Anderson JM; Pillans PI; Williams K; McLachlan AJ; Day RO; taylor P, 2010, 'Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry', Journal of Chromatography, vol. 878, pp. 2363 - 2368, http://dx.doi.org/10.1016/j.jchromb.2010.07.017
2010
Abdul M; Jiang XM; Williams KM; Day RO; Roufogalis B; Liauw WS; Xu H; Matthias A; Lehmann RP; McLachlan AJ, 2010, 'Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 69, pp. 508 - 515, http://dx.doi.org/10.1111/j.1365-2125.2010.03620.x
2010
Reckmann M; Westbrook JI; Koh Y; Lo CM; Day RO, 2009, 'Does Computerized Provider Order Entry Reduce Prescribing Errors for Hospital Inpatients? A Systematic Review', American Medical Informatics Association Annual Symposium Proceedings, vol. 16, pp. 613 - 623, http://dx.doi.org/10.1197/jamia.M3050
2009
Lee P; Greenfield JR; Day RO; Ho K, 2009, 'Weight maintenance in hospitalized geriatric patients treated with beta-blockers', Journal of the American Geriatrics Society, vol. 57, pp. 1125 - 1126, http://dx.doi.org/10.1111/j.1532-5415.2009.02282.x
2009
Osborn M; Day RO; Komesaroff P; Mant A, 2009, 'Do ethical guidelines make a difference to decision-making?', Internal Medicine Journal, vol. 39, pp. 800 - 805, http://dx.doi.org/10.1111/j.1445-5994.2009.01954.x
2009
Indraratna P; Williams KM; Graham GG; Day RO, 2009, 'Hyperuricemia, Cardiovascular Disease and the Metabolic Syndrome', The Journal of Rheumatology, vol. 36, pp. 2842 - 2843, http://dx.doi.org/10.3899/jrheum.090500
2009
Osborn M; Day RO; Westbrook JI, 2009, 'Are specialist physicians missing out on the e-Health boat?', Internal Medicine Journal, vol. 39, pp. 655 - 661, http://dx.doi.org/10.1111/j.1445-5994.2009.02023.x
2009
Hancock M; Maher C; Latimer J; Mclachlan AJ; Day RO; Davies R, 2009, 'Can predictors of response to NSAIDs Be identified in patients with acute low back pain?', Clinical Journal of Pain, vol. 25, pp. 659 - 665, http://dx.doi.org/10.1097/AJP.0b013e3181a7ee3a
2009
Day RO, 2009, 'India: Emerging centre of drug develpment', Journal of Pharmacy Practice and Research, vol. 39, pp. 262 - 263
2009
Day RO, 2009, 'Adherence to urate-lowering therapy', Southern Medical Journal, vol. 102, pp. 114 - 115, http://dx.doi.org/10.1097/SMJ.0b013e31819042a0
2009
Lee M; Graham GG; Williams KM; Day RO, 2008, 'A benefit-risk assessment of benzbromarone in the treatment of gout - was its withdrawal from the market in the best interest of patients?', Drug Safety, vol. 31, pp. 643 - 665, http://dx.doi.org/10.2165/00002018-200831080-00002
2008
Lu CY; Williams KM; Day RO, 2008, 'Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia', International Journal of Rheumatology, vol. 11, pp. 11 - 14, http://dx.doi.org/10.1111/j.1756-185X.2008.00322.x
2008
Day RO; Fransen M; Zochling J; March L, 2008, 'Osteoarthritis: NSAIDs, paracetamol or other treatment approaches?', Medicine Today, vol. 9, pp. 71 - 74
2008
McLachlan AJ; Day RO; Williams KM; Graham GG, 2008, 'Maximising gout therapy', Australian Journal of Pharmacy, vol. 89, pp. 86 - 88
2008
Chung Y; Stocker S; Graham GG; Day RO, 2008, 'Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy', American Journal of the Medical Sciences, vol. 335, pp. 219 - 226, http://dx.doi.org/10.1097/MAJ.0b013e31815acb10
2008
Lu CY; Macneill P; Williams K; Day R, 2008, 'Access to high cost medicines in Australia: Ethical perspectives', Australia and New Zealand Health Policy, vol. 5, http://dx.doi.org/10.1186/1743-8462-5-4
2008
Abdul M; Jiang XM; Day RO; Roufogalis B; Liauw WS; Xu H; Mclachlan AJ, 2008, 'Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects', British Journal of Pharmacology, vol. 154, pp. 1691 - 1700, http://dx.doi.org/10.1038/bjp.2008.210
2008
Magrabi F; Westbrook JI; Kidd MR; Day RO; Coiera E, 2008, 'Long-term patterns of online evidence retrieval use in general practice: A 12-month study', Journal of Medical Internet Research, vol. 10, http://dx.doi.org/10.2196/jmir.974
2008
Chung YW; Lu CY; Graham GG; Mant A; Day RO, 2008, 'Utilization of allopurinol in the Australian community', Internal Medicine Journal, vol. 38, pp. 388 - 395, http://dx.doi.org/10.1111/j.1445-5994.2008.01641.x
2008
Stocker S; Williams KM; Mclachlan AJ; Graham GG; Day RO, 2008, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects', Clinical Pharmacokinetics, vol. 47, pp. 111 - 118, http://dx.doi.org/10.2165/00003088-200847020-00004
2008
Xu H; Liauw WS; Murray M; Day RO; Mclachlan AJ, 2008, 'Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide', British Journal of Pharmacology, vol. 153, pp. 1579 - 1586, http://dx.doi.org/10.1038/sj.bjp.0707685
2008
Mikhail S; Zwar NA; Vagholkar S; Dennis SM; Day RO, 2007, 'Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma', Medical Journal of Australia, vol. 187, pp. 160 - 163
2007
Hancock M; Maher CG; Latimer J; Mclachlan AJ; Cooper C; Day RO; Spindler M; McAuley J, 2007, 'Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial', Lancet, vol. 370, pp. 1638 - 1643, http://dx.doi.org/10.1016/S0140-6736(07)61686-9
2007
Lu C; Ritchie JE; Williams KM; Day RO, 2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-26
2007
Murnion BP; Granot R; Day RO, 2007, 'Utility of urine drug screening: A clinical audit', EMA - Emergency Medicine Australasia, vol. 19, pp. 246 - 252, http://dx.doi.org/10.1111/j.1742-6723.2007.00922.x
2007
Kaye K; Lu C; Day R, 2007, 'Can we deny patients expensive drugs? [2]', Australian Prescriber, vol. 30, pp. 60
2007
Lu CY; Williams KM; Day RO, 2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, vol. 4, http://dx.doi.org/10.1186/1743-8462-4-2
2007
Day R; Lu CY; Pearce G; Grainger D, 2007, 'Pharmaceutical benefits scheme: Rapid change and impetus towards achieving QUM', Journal of Pharmacy Practice and Research, vol. 37, pp. 4 - 6, http://dx.doi.org/10.1002/j.2055-2335.2007.tb00644.x
2007
Graham GG; Day RO, 2007, 'Expert comment [6]', Australian Prescriber, vol. 30, pp. 61 - 62
2007
Granot R; Day RO; Cohen ML; Murnion B; Garrick R, 2007, 'Targeted pharmacotherapy of evoked phenomena in neuropathic pain: A review of the current evidence', Pain Medicine, vol. 8, pp. 48 - 64, http://dx.doi.org/10.1111/j.1526-4637.2007.00156.x
2007
Day RO; Graham G; Williams K, 2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, vol. 30, pp. 32
2007
Lu CY; Williams KM; Day RO, 2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, vol. 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x
2007
Miners JO; Day RO, 2007, 'Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes', British Journal of Clinical Pharmacology, vol. 63, pp. 380 - 381, http://dx.doi.org/10.1111/j.1365-2125.2006.02737.x
2007
Tan E; Day RO; Brien JE, 2007, 'Prioritising drug and therapeutics committee (DTC) decisions: a national survey', Pharmacy World and Science, vol. 29, pp. 90 - 96, http://dx.doi.org/10.1007/s11096-006-9074-y
2007
Kelman CW; Pearson S; Day RO; D Arcy C; Holman JW; Kliewer E; Henry D, 2007, 'Evaluating medicines: let`s use all the evidence', Medical Journal of Australia, vol. 186, pp. 249 - 252
2007
Pearson S; Ringland C; Kelman CW; Mant A; Lowinger J; Stark H; Nichol G; Day RO; Henry DA, 2007, 'Patterns of analgesic and anti-inflammatory medicine use by Australian veterans', Internal Medicine Journal, vol. 37, pp. 798 - 805, http://dx.doi.org/10.1111/j.1445-5994.2007.01516.x
2007
Day RO; Williams KM, 2007, 'Open-label extension studies - Do they provide meaningful information on the safety of new drugs?', Drug Safety, vol. 30, pp. 93 - 105, http://dx.doi.org/10.2165/00002018-200730020-00001
2007
Day RO; Graham GG; Hicks M; Mclachlan AJ; Stocker S; Williams KM, 2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, vol. 46, pp. 623 - 644, http://dx.doi.org/10.2165/00003088-200746080-00001
2007
Coiera E; Magrabi F; Westbrook JI; Kidd MR; Day RO, 2006, 'Protocol for the Quick Clinical study - a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice', BMC Medical Informatics and Decision Making, vol. 6, http://dx.doi.org/10.1186/1472-6947-6-33
2006
Lu CY; Williams KM; Day RO, 2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200457&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
Mcneill PM; Kerridge IH; Henry DA; Stokes B; Hill SR; Newby D; Macdonald GJ; Day RO; Maguire J; Henderson KM, 2006, 'Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia', Internal Medicine Journal, vol. 26, pp. 571 - 578, http://dx.doi.org/10.1111/j.1445-5994.2006.01151.x
2006
Loboz K; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht J; Zanger U; McLachlan AJ, 2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, vol. 80, pp. 75 - 84, http://dx.doi.org/10.1016/j.clpt.2006.03.010
2006
Strand V; Conaghan P; Lohmander L; Koutsoukos A; Hurley F; Bird H; Brooks PM; Day RO; Puhl W; Band P, 2006, 'An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the kneel', Osteoarthritis and Cartilage, vol. 14, pp. 859 - 866, http://dx.doi.org/10.1016/j.joca.2006.02.012
2006
Reicin A; Shapiro D, 2006, 'Response to expression of concern regarding VIGOR study.', N Engl J Med, vol. 354, pp. 1196 - 1199, https://www.ncbi.nlm.nih.gov/pubmed/16544387
2006
Kaye KI; Lu CY; Day RO, 2006, 'Can we deny patients expensive drugs?', Australian Prescriber, vol. 29, pp. 146 - 148, http://dx.doi.org/10.18773/austprescr.2006.087
2006
Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis SR; Day RO, 2006, 'In reply [9]', Medical Journal of Australia, vol. 184, pp. 44 - 45
2006
Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis SR; Day RO, 2006, 'Pethidine in emergency departments: promoting evidence-based prescribing - Reply', Medical Journal of Australia, vol. 184, pp. 44 - 45, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000235707000016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
Lu CY; Williams KM; Day RO, 2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?', Internal Medicine Journal, vol. 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x
2006
Bombardier C; Laine L; Burgos-Vargas R; Davis BE; Day RO; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien T; Schnitzer TJ; Weaver AJ; Reicin A; Shapiro D, 2006, 'Response to expression of concern regarding VIGOR study', New England Journal of Medicine, vol. 354, pp. 1196 - 1198, http://dx.doi.org/10.1056/NEJMc066096
2006
Lu CY; Williams KM; Day RO, 2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, vol. 184, pp. 411 - 413
2006
Lu CY; Williams KM; Day RO, 2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, vol. 15, pp. S213 - S213, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000240281200458&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2006
Lu CY; Ritchie JE; Williams KM; Day RO, 2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, vol. 2, pp. 1 - 8, http://dx.doi.org/10.1186/1743-8462-2-28
2005
Lassere MN; Johnson KR; Woodworth G; Furst DE; Fries J; Kirwan J; Tugwell P; Day RO; Brooks P, 2005, 'Challenges and Progress in adverse event ascertainment and reporting in clinical trials', Journal of Rheumatology, vol. 32, pp. 2030 - 2032
2005
Lu CY; Williams K; Day R, 2005, 'Evaluation of access to high-cost medicines in Australia using national claims data', VALUE IN HEALTH, vol. 8, pp. A28 - A28, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233021700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2005
Hancock M; Maher C; Latimer J; Mclachlan AJ; Cooper C; Day RO; Spindler M; McAuley J, 2005, 'Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]', BMC Musculoskeletal Disorders, vol. 6, http://dx.doi.org/10.1186/1471-2474-6-57
2005
Jiang X; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; McLachlan AJ, 2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 59, pp. 425 - 432, http://dx.doi.org/10.1111/j.1365-2125.2005.02322.x
2005
Ritchie JE; Lu CY; Williams K; Day RO, 2005, 'Sample size is beside the point in policy development research', Australian and New Zealand Journal of Public Health, vol. 29, pp. 583 - 583, http://dx.doi.org/10.1111/j.1467-842X.2005.tb00257.x
2005
Day RO; Graham GG, 2005, 'Paracetamol should be first-line therapy in osteoarthritis', Medical Journal of Australia, vol. 182, pp. 198 - 199
2005
Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis S; Day RO, 2005, 'Pethidine in emergency departments: promoting evidence-based prescribing', Medical Journal of Australia, vol. 183, pp. 129 - 133
2005
Henry D; Kerridge IH; Hill S; Mcneill PM; Doran E; Newby D; Henderson K; Maguire J; Stokes B; Macdonald GJ; Day RO, 2005, 'Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience', Medical Journal of Australia, vol. 182, pp. 557 - 560
2005
Kerridge IH; Maguire J; Newby D; Mcneill PM; Henry D; Hill SB; Day RO; Macdonald GJ; Stokes B; Henderson K, 2005, 'Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations', Internal Medicine Journal, vol. 35, pp. 206 - 210, http://dx.doi.org/10.1111/j.1444-0903.2004.00799.x
2005
Day R; Adams S, 2005, 'The birth of ibuprofen', Australian Journal of Pharmacy, vol. 86, pp. 84 - 85
2005
Lu CY; Ritchie JE; Williams KJ; Day RE, 2005, 'Targeted access to high-cost medicines in Australia: Early analysis from a qualitative study', Value in Health, vol. 8, pp. A28 - A28, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233021700089&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2005
Hamama A; Ray J; Day RO; Brien JE, 2005, 'Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography', Journal of Chromatographic Science, vol. 43, pp. 351 - 354, http://dx.doi.org/10.1093/chromsci/43.7.351
2005
Graham GG; Day RO, 2005, 'Tolerability of paracetamol', Drug Safety, vol. 28, pp. 227 - 240, http://dx.doi.org/10.2165/00002018-200528030-00004
2005
Lassere MN; Johnson KR; Boers M; Carlton KE; Day RO; Wit M; Edwards I; Fries J; Furst DE; Kirwan J; Tugwell P; Woodworth G; Brooks P, 2005, 'Standardized Assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module Update', Journal of Rheumatology, vol. 32, pp. 2037 - 2041
2005
Henry D; Doran E; Kerridge IH; Hill SB; Mcneill PM; Day RO, 2005, 'Ties that bind - Multiple relationships between clinical researchers and the pharmaceutical industry', Archives of Internal Medicine, vol. 165, pp. 2493 - 2496, http://dx.doi.org/10.1001/archinte.165.21.2493
2005
Tan EL; Day RO; Brien JAE, 2005, 'Perspectives on Drug and Therapeutics Committee policy implementation', Research in Social and Administrative Pharmacy, vol. 1, pp. 526 - 545, http://dx.doi.org/10.1016/j.sapharm.2005.09.001
2005
Day RO; Birkett DJ; Miners J; Shenfield GM; Henry DA; Seale JP, 2005, 'Access to medicines and high-quality therapeutics: Global responsibilities for clinical pharmacology', Medical Journal of Australia, vol. 182, pp. 322 - 323
2005
Lu CY; Williams KM; March LM; Bertouch JV; Day RO, 2004, 'Subsided access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?', Medical Journal of Australia, vol. 181, pp. 457 - 457
2004
Lu CY; Williams KM; Day RO; March LM; Sansom L; Bertouch JV, 2004, 'Access to high cost drugs in Australia', British Medical Journal: Clinical Research, vol. 329, pp. 415 - 416
2004
Day RO; Brooks P; Conaghan PG; Petersen M, 2004, 'A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee', Journal of Rheumatology, vol. 31, pp. 775 - 782
2004
Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin', Clinical and Experimental Pharmacology and Physiology, vol. 31, pp. A227 - A227, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000225490400052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2004
Day RO; Graham GG, 2004, 'The vascular effects of COX-2 selective inhibitors', Australian Prescriber, vol. 27, pp. 142 - 145, http://dx.doi.org/10.18773/austprescr.2004.119
2004
Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Erratum: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (British Journal of Clinical Pharmacology (2004) 57 (592-599))', British Journal of Clinical Pharmacology, vol. 58, pp. 102, http://dx.doi.org/10.1111/j.1365-2125.2004.02155.x
2004
Liauw WS; Williams KM; Day RO, 2004, 'Protocol Appraisal: A Study Site's Viewpoint', Applied Clinical Trials, vol. 13, pp. 34 - 42
2004
Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, vol. 5, pp. 91 - 98, http://dx.doi.org/10.1310/1FLN-8KFC-5HEQ-K19J
2004
Lee EJ; Williams KM; Day RO; Graham GG; Champion D, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man (Reprintedfrom Br J Clin Pharmacol, vol 19, pg 669-674, 1985)', British Journal of Clinical Pharmacology, vol. 58, pp. S759 - S764, http://dx.doi.org/10.1111/j.1365-2125.2004.02288.x
2004
Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, vol. 57, pp. 592 - 599, http://dx.doi.org/10.1111/j.1365-2125.2003.02051.x
2004
Tan E; Day RO; Brien JE, 2004, 'Stakeholder Opinions on the Implementation of Drug and Therapeutics Committee Decisions', Journal of Pharmacy Practice and Research, vol. 34, pp. 178 - 182, http://dx.doi.org/10.1002/jppr2004343178
2004
Wren BG; Day RO; Mclachlan AJ; Williams KM, 2003, 'Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women', Climacteric, vol. 6, pp. 104 - 111, http://dx.doi.org/10.1080/cmt.6.2.104.111
2003
Graham GG; Scott KF, 2003, 'Alcohol and paracetamol', Australian Prescriber, vol. 27, pp. 14 - 15
2003
Day RO, 2003, 'Pharmaceutical health and rational use of medicines committee', Journal of Pharmacy Practice and Research, vol. 33, pp. 87 - 89, http://dx.doi.org/10.1002/jppr200333287
2003
Day RO, 2003, 'Where are we in 2003? Distinction from NSAIDs becoming blurred', Arthritis Research and Therapy, vol. 5, pp. 116 - 119
2003
Sasongko L; Williams KM; Day RO; Mclachlan AJ, 2003, 'Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques', British Journal of Pharmacology, vol. 56, pp. 551 - 561, http://dx.doi.org/10.1046/j.1365-2125.2003.01930.x
2003
Graham GG; Scott KF; Day RO, 2003, 'Tolerability of Paracetamol', Drugs, vol. 63, pp. 43 - 46, http://dx.doi.org/10.2165/00003495-200363992-00007
2003
Liauw WS; Day RO, 2003, 'Adverse event reporting in clinical trials: room for improvement', Medical Journal of Australia, vol. 179, pp. 426 - 428
2003
Day R, 2003, 'COX-2: Where are we in 2003? Distinction from NSAIDs becoming blurred', Arthritis Research and Therapy, vol. 5, pp. 116 - 119
2003
Tan E; Day RO; Brien JE, 2003, 'Drug and therapeutics committees - are they fulfilling their potential to improve the quality use of medicines?', International Journal of Pharmacy Practice, vol. 11, pp. 175 - 181, http://dx.doi.org/10.1211/0022357022205
2003
Day RO, 2003, 'Hypertension in the patient with arthritis: Have we underestimated its significance?', Journal of Rheumatology, vol. 30, pp. 642 - 644
2003
Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors - Reply', MEDICAL JOURNAL OF AUSTRALIA, vol. 177, pp. 573 - 573, http://dx.doi.org/10.5694/j.1326-5377.2002.tb04961.x
2002
Day RE; Rogers PJ; Dawes IW; Higgins VJ, 2002, 'Molecular Analysis of Maltotriose Transport and Utilisation by Saccharomyces cerevisiae', Applied and Environmental Microbiology, vol. 68, pp. 5326 - 5335, http://dx.doi.org/10.1128/AEM.68.11.5326-5335.2002
2002
Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: considerations for the safe use and prescribing of COX-2 specific inhibitors', Medical Journal of Australia, vol. 176, pp. 332 - 334
2002
Day R, 2002, 'Adverse reactions to TNF-α inhibitors in rheumatoid arthritis', Lancet, vol. 359, pp. 540 - 541, http://dx.doi.org/10.1016/S0140-6736(02)07718-8
2002
Day RE; Higgins VJ; Rogers PJ; Dawes IW, 2002, 'Characterisation of the putative maltose transporters encoded by YDL247w and YJR160c', Yeast, vol. 19, pp. 1015 - 1027, http://dx.doi.org/10.1002/yea.894
2002
Vitry AI; Hurley E; Gazarian M; Kaye KI; Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: Considerations for the safe use and prescribing of COX-2-specific inhibitors (multiple letters)', Medical Journal of Australia, vol. 177, pp. 572 - 573
2002
Barraclough D; Bertouch J; Brooks P; Brown MA; Cleland L; Clemens LE; Crowley SJ; Day RO; DeJager JP; Edmonds JP; Fletcher P; Franks GR; Harris DC; Horowitz JD; Johnston MD; Kerr SJ; Littlejohn GO; Macdonald GJ; McColl GJ; Sambrook PN; Shakib S; Verso MW; Yeomans ND, 2002, 'Considerations for the safe prescribing and use of COX-2-specific inhibitors', Medical Journal of Australia, vol. 176, pp. 328 - 331
2002
Day R, 2002, 'Another selective COX-2 inhibitor: More questions than answers?', Journal of Rheumatology, vol. 29, pp. 1581 - 1582
2002
Carmichael SJ; Beal J; Day RO; Tett SE, 2002, 'Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate', Journal of Rheumatology, vol. 29, pp. 2077 - 2083
2002
Graham GG; Graham RM; Day RO, 2002, 'Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)', Current Pharmaceutical Design, vol. 8, pp. 1063 - 1075, http://dx.doi.org/10.2174/1381612023394917
2002
Lawrie MM; McKeough GN; Jones DB; Brooks PM; Day RO, 2001, 'COX-2 inhibitors (multiple letters)', Medical Journal of Australia, vol. 174, pp. 367 - 369
2001
Williams KM; Cooper S; Parisis K; Handel M; Day RO, 2001, 'The skin suction blister: A human model of inflammation', Clinical Pharmacology and Therapeutics, vol. 69
2001
Lipani JA; Strand V; Johnson KA; Woodworth T; Furst DE; Singh G; Day RO; Brooks PM, 2001, 'OMERACT Drug Safety Working Party. A proposal for developing a large ptient population cohort for longterm safety monitoring in rheumatoid arthritis.', Journal of Rheumatology, pp. 1170 - 1173
2001
Woodworth T; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day RO; Lipani JA; Brooks PM, 2001, 'Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group march 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies', Journal of Rheumatology, vol. 28, pp. 1163 - 1169
2001
Welch V; Singh G; Strand V; Fries JW; Boers M; Ramey D; Day RO; Brooks PM; Tugwell P; Clinch J; Kristjansson B, 2001, 'Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index', Journal of Rheumatology, vol. 28, pp. 1188 - 1191
2001
Day RO, 2001, 'Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A rheumatologists perspective', Clinical and Experimental Rheumatology, vol. 19, pp. 59 - 62
2001
Brooks PM; Day RO, 2001, 'COX-2 inhibitors - In reply', MEDICAL JOURNAL OF AUSTRALIA, vol. 174, pp. 368 - 369, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143324.x
2001
Day RO; Mashford ML, 2001, 'Pharmacotherapeutics: what a difference five decades makes!', Medical Journal of Australia, vol. 174, pp. 48 - 51
2001
Brooks PM; Day RO, 2001, 'Drug safety module: Summary and recommendations', Journal of Rheumatology, vol. 28, pp. 1192 - 1193
2001
Lipani JA; Strand V; Woodworth T; Furst DE; Singh G; Johnson KA; Day RO; Brooks PM, 2000, 'A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis', Journal of Rheumatology, vol. 27, pp. 827 - 830, https://www.ncbi.nlm.nih.gov/pubmed/10782801
2000
Day RO; Graham GG; Whelton A, 2000, 'The position of paracetamol in the world of analgesics', American Journal of Therapeutics, vol. 7, pp. 51 - 54, http://dx.doi.org/10.1097/00045391-200007020-00002
2000
Tett S; Cutler D; Beck C; Day RO, 2000, 'Concentration effect relationship of hydroxychloroquine in patients with rheumatoid arthritis - A prospective, dose-ranging study', Journal of Rheumatology, vol. 27, pp. 1656 - 1660
2000
Day RO; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels BA; Bolognese J; Krupa D; Seidenberg B; Ehrich EW, 2000, 'A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis', Archives of Internal Medicine, vol. 160, pp. 1781 - 1787, http://dx.doi.org/10.1001/archinte.160.12.1781
2000
Day RO; Graham GG; Whelton A, 2000, 'The position of paracetamol in the world of analgesics.', American Journal of Therapeutics, pp. 51 - 54
2000
Day RO, 2000, 'How to make the most of a visit from a pharmaceutical company representative', Australian Prescriber, vol. 23, pp. 97 - 99, http://dx.doi.org/10.18773/austprescr.2000.114
2000
Davies NP; Mclachlan AJ; Day RO; Williams KM, 2000, 'Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor.', Clinical Pharmacokinetics, vol. 38, pp. 225 - 242, http://dx.doi.org/10.2165/00003088-200038030-00003
2000
Day RO, 2000, 'COX-2 Specific inhibitors and the hospital pharmacist', Australian Journal of Hospital Pharmacy, vol. 30, pp. 41 - 43, http://dx.doi.org/10.1002/jppr200030241
2000
Bombardier C; Laine L; Reicin A; Shapiro D; Burgos-Vargas R; Davis BE; Day RO; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien T; Schnitzer TJ, 2000, 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis', New England Journal of Medicine, vol. 343, pp. 1520 - 1528, http://dx.doi.org/10.1056/NEJM200011233432103
2000
Day R, 2000, 'COX-2 Specific Inhibitors: Should I Prescribe Them?', Current Therapeutics, vol. 41, pp. 9 - 11
2000
Day RO, 2000, 'COX-2 Specific inhibitors. Safer anti-inflammatory therapy?', Medicine Today, pp. 31 - 38
2000
O Sullivan AJ; Kennedy M; Day RO; Case J; Corrigan B; Wodak AD, 2000, 'Medical assessment of anabolic-androgenic steroid users', Medical Journal of Australia, vol. 173, pp. 323 - 327
2000
Welch SA; Novy M; Preiz P; Quinn DI; Whicker SD; Brown S; Day RO, 2000, 'Promoting rational prescribing by emergency department junior medical officers', Australian Journal of Hospital Pharmacy, vol. 30, pp. 262 - 270, http://dx.doi.org/10.1002/jppr2000306262
2000
Day RO, 2000, 'COX-2 inhibitors: When should they be prescribed?', Current Therapeutics, pp. 9 - 11
2000
Brooks PM; Day RO, 2000, 'COX-2 inhibitors', Medical Journal of Australia, vol. 173, pp. 433 - 436
2000
Peterson G; Day R, 2000, 'COX-2 specific inhibitors and cancer (multiple letters)', Australian Journal of Hospital Pharmacy, vol. 30, pp. 120, http://dx.doi.org/10.1002/jppr2000303120
2000
Brooks PM; Emery P; Evans JF; Fenner H; Hawkey CJ; Patrono C; Smolen J; Breedveld F; Day RO; Dougados M; Ehrich EW; Gijon-Banos J; Kvien T; Van Rijswijk MH; Warner T; Zeidler H, 1999, 'Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2', Rheumatology, vol. 38, pp. 779 - 788, https://www.ncbi.nlm.nih.gov/pubmed/10501435
1999
Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks PM; Day RO; Strand V; Wells G, 1999, 'Patient based methods for assessing adverse events in clinical trials in Rheumatology. Progress report for the Omeract Drug Toxicity Working Party', Journal of Rheumatology, vol. 26, pp. 207 - 209
1999
Day RO; Rowett D; Roughead EE, 1999, 'Towards the safer use of non-steroidal anti-inflammatory drugs', Journal of Quality in Clinical Practice, vol. 19, pp. 51 - 53, http://dx.doi.org/10.1046/j.1440-1762.1999.00287.x
1999
Graham GG; Day RO; Milligan MK; Ziegler JB; Kettle AJ, 1999, 'Current Concepts of the actions of paracetamol (acetaminophen) and NSAIDS', Inflammopharmacology, vol. 7, pp. 255 - 263, http://dx.doi.org/10.1007/s10787-999-0008-x
1999
Day RO; Brooks PM; Petersen M; Conaghan P, 1999, 'Efficacy and safety of intraarticular hyaluronic acid in osteoarthritis', Clinical Pharmacology and Therapeutics, vol. 65, pp. 172, http://dx.doi.org/10.1016/S0009-9236(99)80220-3
1999
Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks PM; Day RO; Strand V; Wells G, 1999, 'Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress for the OMERACT drug toxicity working party', Journal of Rheumatology, pp. 207 - 209
1999
Williams KM; Day RO; Roberts LK; Harbin JA, 1999, 'A comparison of the efficacy of α-ketobutyric acid (KBA), nordihidro-guaiaretic acid (NDGA), salicylic acid (SA), and placebo (P) in the accelerated removal of corns', Clinical Pharmacology and Therapeutics, vol. 65, pp. 122, http://dx.doi.org/10.1016/S0009-9236(99)80022-8
1999
Browne GS; Nelson CJ; Nguyen TM; Ellis B; Day RO; Williams KM, 1999, 'Stereoselective and substrate-dependent inhibition of hepatic mitochondrial B-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and ketorolac', Biochemical Pharmacology, vol. 57, pp. 837 - 844, http://dx.doi.org/10.1016/S0006-2952(98)00342-6
1999
Erb K; Brugger R; Williams KM; Geisslinger G, 1999, 'Stereoselective disposition of tiaprofenic acid enantiomers in rats', Chirality, vol. 11, pp. 103 - 108
1999
Brooks P; Emery P; Evans JF; Fenner H; Hawkey CJ; Patrono C; Smolen J; Breedveld F; Day R; Dougados M; Ehrich EW; Gijon-Baños J; Kvien TK; Van Rijswijk MH; Warner T; Zeidler H, 1999, 'The International Consensus Meeting on the Mode of Action of COX-2 Inhibition, 5-6 December 1997: Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2', Rheumatology, vol. 38, pp. 779 - 788, http://dx.doi.org/10.1093/rheumatology/38.8.779
1999
Day RO; Mclachlan AJ; Graham GG; Williams KM, 1999, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid', Clinical Pharmacokinetics, vol. 36, pp. 191 - 210, http://dx.doi.org/10.2165/00003088-199936030-00002
1999
Brooks PM, 1998, 'Pharmaceutical company promotion: striking a balance', Australian and New Zealand Journal of Medicine, vol. 28, pp. 291 - 293, http://dx.doi.org/10.1111/j.1445-5994.1998.tb01950.x
1998
Weekes LM; Brooks C; Day RO, 1998, 'Indicators for Drug and Therapeutics Committees', British Journal of Clinical Pharmacology, vol. 45, pp. 393 - 398, http://dx.doi.org/10.1046/j.1365-2125.1998.00699.x
1998
Carmody JJ; Walker JS; Sheather-Reid RB; Vial JH; Day RO, 1998, 'Non-steroidal anti-inflammatory drugs (NSAIDs): Support for the concept of 'responders' and 'non-responders', NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, vol. 358, pp. R450 - R450, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000075207800302&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1998
Quinn DI; Day RO, 1998, 'A GP`s guide to clinically important drug interactions', Modern Medicine of Australia, vol. 41, pp. 89 - 103
1998
Scheuerer S; Williams KM; Brugger R; Mclachlan AJ; Brune K; Day RO; Geisslinger G, 1998, 'Effect of clofibrate on the chiral inversion of ibuprofen in rats', Journal of Pharmacology and Experimental Therapeutics, vol. 284, pp. 1132 - 1138
1998
Quinn DI; Day RO, 1998, 'Drug Interactions Alert', First Ed., pp. 38
1998
Bramley-Moore S; Wodak AD; Day RO; Lauchlan RL, 1998, 'Patterns of analgesic prescribing patients with chronic non-malignant pain in NSW', Australian Journal of Hospital Pharmacy, vol. 28, pp. 83 - 88
1998
Bramley-Moore S; Wodak AD; Day RO; Lauchlan RL, 1998, 'Patterns of analgesic prescribing for patients with chronic non-malignant pain in NSW', Australian Journal of Hospital Pharmacy, pp. 83 - 88
1998
Weekes LM; Day RO, 1998, 'The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees: an Australian perspective.', Drug Safety, vol. 18, pp. 153 - 159, http://dx.doi.org/10.2165/00002018-199818030-00001
1998
Day RO; Williams KM; Campbell TJ, 1998, 'The death of a normal healthy volunteer in a human research project: implications for Australian clinical research', Medical Journal of Australia, vol. 168, pp. 449 - 451
1998
Weekes LM; Brooks C; Day RO, 1998, 'Indicators for Drug and Therapeutics Committees', British Journal of Clinical Pharmacology, vol. 45, pp. 393 - 398, http://dx.doi.org/10.1046/j.1365-2125.1998.00699.x
1998
Quinn DI; Markus R; Day RO, 1998, 'Antiepileptic therapy', Current Therapeutics, vol. 39, pp. 23 - 37
1998
Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', Clinical Pharmacology and Therapeutics, vol. 61, pp. 160
1997
Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 61, pp. PI93 - PI93, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WJ68400093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1997
Quinn DE; Wodak AD; Day RO, 1997, 'Pharmocokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users', Clinical Pharmacokinetics, pp. 344 - 400
1997
Shackel NA; Day RO; Kellett B; Brooks PM, 1997, 'Copper-salicylate gel for pain relief in osteoarthritis - a randomised controlled trial.', Medical Journal of Australia, vol. 167, pp. 134 - 136
1997
Day RE; Gero AM, 1997, 'Stimulated transport of hypoxanthine in Crithidia luciliae: Relationship to purine stress', Parasitology, vol. 114, pp. 19 - 27, http://dx.doi.org/10.1017/S003118209600827X
1997
Quinn DE; Wodak AD; Day RO, 1997, 'Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.', Clinical Pharmacokinetics, pp. 344 - 400
1997
Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis - support', Arthritis Care & Research, pp. 1944 - 1954
1997
Donnelly R; Williams KM; Baker A; Badcock CA; Day RO; Seale JP, 1997, 'Effects of budesonide and fluticasoue on 24-hour plasma cortisol: A dose-response study.', American Journal of Respiratory and Critical Care Medicine, vol. 156, pp. 1746 - 1751, http://dx.doi.org/10.1164/ajrccm.156.6.9703003
1997
Birkett DJ; Miners JO; Valente KJ; Lillywhite KJ; Day RO, 1997, '1-Methylxanthine Derived from Caffeine as a Pharmacodynamic Probe of', British Journal of Clinical Pharmacology, vol. 43, pp. 197 - 200
1997
Lehmann T; Day RO; Brooks PM, 1997, 'Toxicity of antirheumatic drugs', Medical Journal of Australia, vol. 166, pp. 378 - 383
1997
Wodak AD; Quinn DE; Day RO, 1997, 'Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.', Clinical Pharmacokinetics, vol. 33, pp. 344 - 400, http://dx.doi.org/10.2165/00003088-199733050-00003
1997
Day R; Mant A; Whicker S; Primrose J, 1997, 'Quality assessment in therapeutics: Antibiotic use.', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 61, pp. PII79 - PII79, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WJ68400306&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1997
Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "nonresponders".', Arthritis Rheum, vol. 40, pp. 1944 - 1954, http://dx.doi.org/10.1002/art.1780401105
1997
Day R; Mant A; Whicker S; Primrose J, 1997, 'Quality assessment in therapeutics: Antibiotic use', Clinical Pharmacology and Therapeutics, vol. 61, pp. 214
1997
Lehmann T; Day RO; Brooks PM, 1997, 'Rheumatology 12. Toxicity of antirheumatic', Medical Journal of Australia, vol. 166, pp. 378 - 383, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WT68100013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1997
Gero AM; Day RE; Hall ST, 1997, 'Stimulated transport of adenosine, guanosine and hypoxanthine in Crithidia luculiae: Metabolic machinery in which the parasite has a distinct advantage over the host', International Journal for Parasitology, vol. 27, pp. 241 - 249, http://dx.doi.org/10.1016/S0020-7519(96)00153-1
1997
Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: Support for the concept of 'responders' and 'nonresponders'', Arthritis and Rheumatism, vol. 40, pp. 1944 - 1954, http://dx.doi.org/10.1002/art.1780401105
1997
Conaghan PG; Crotty M; Oh E; Day RO; Brooks PM, 1997, 'Anti-rheumatic drug-prescribing behaviour of australasian rheumatologists 1984-1994.', British Journal of Rheumatology, vol. 36, pp. 487 - 490
1997
Bellamy N; Bachmeier C; Brooks PM; Browne CD; Cohen ML; March L; Conaghan PG; Day RO; Campbell J, 1997, 'Osteoarthritis antirheumatic drug trials: Effects of a standardized instructional videotape on the reliability of observer-dependent outcome measures', Inflammopharmacology, vol. 5, pp. 285 - 295, http://dx.doi.org/10.1007/s10787-997-0006-9
1997
Johnson AG; Nguyen TM; Day RO, 1996, 'Evaluation of the Takeda TM-2420 in the Elderly', Journal of Hypertension, vol. 10, pp. 61 - 61
1996
Walker JW; Chandler A; Wilson J; Binder W; Day RO, 1996, 'Effect of u-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats', Inflammation Research, vol. 45, pp. 557 - 563, http://dx.doi.org/10.1007/BF02342227
1996
Mcmanus PA; Primrose JG; Henry D; Birkett DJ; Lindner J; Day RO, 1996, 'Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994, A report from the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory', Medical Journal of Australia, vol. 164, pp. 589 - 592
1996
Carey DL; Day RO; Bowden FJ, 1996, 'Common drug interactions in HIV medicine', MEDICAL JOURNAL OF AUSTRALIA, vol. 164, pp. 605 - 606, http://dx.doi.org/10.5694/j.1326-5377.1996.tb122205.x
1996
Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations - Reply', JOURNAL OF RHEUMATOLOGY, vol. 23, pp. 1827 - 1828, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VL78300035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1996
Day RO; Brown S; Weekes LM, 1996, 'Drug committees - the key to quality use of medicines?', Australian Journal of Hospital Pharmacy, pp. 622 - 623
1996
Johnson AG; Nguyen TM; Owe-Young R; Williamson DJ; Day RO, 1996, 'Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-I', Journal of Hypertension, vol. 10, pp. 257 - 261
1996
Graham GG; Day RO; Wong H; Mclachlan AJ; Bergendal L; Miners JO; Birkett DJ, 1996, 'Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects', British Journal of Clinical Pharmacology, vol. 41, pp. 299 - 304
1996
Simkin PA; Bassett JE; Lapicque F; Bertin P; Netter P; Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentration in plasma and synovial fluid and effects on prostanoid concentrations [1]', Journal of Rheumatology, vol. 23, pp. 1826 - 1828
1996
Handel ML; Watts CKW; Sivertsen S; Day RO; Sutherland RL, 1996, 'D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding', Molecular Pharmacology, vol. 50, pp. 501 - 505
1996
Walker JW; Lockton A; Nguyen L; Day RO, 1996, 'Effect of single and multiple doses of ibuprofen in chronic spinal pain patients', Analgesia, vol. 2, pp. 93 - 101
1996
Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV. Common drug interactions in HIV medicine.', Med J Aust, vol. 164, pp. 605 - 606, https://www.ncbi.nlm.nih.gov/pubmed/8637465
1996
Tett S; Day RO; Cutler D, 1996, 'Hydroxychloroquine relative bioavailability: within subject reproducibility', British Journal of Clinical Pharmacology, vol. 41, pp. 244 - 246, http://dx.doi.org/10.1111/j.1365-2125.1996.tb00190.x
1996
Handel ML; Watts CG; Silversten S; Day RO; Sutherland RL, 1996, 'D-Penicillamine causes free-radical-dependent inactivation of activator protein-1 DNA binding', Molecular Pharmacology, pp. 1 - 5
1996
Walker JS; Day RO; Moore UJ; Marsh VR; Ashton CH; Seymour RA, 1996, 'Experimental pain techniques [2]', British Journal of Clinical Pharmacology, vol. 41, pp. 349 - 350
1996
Walker JW; Day RO, 1996, 'Experimental pain techniques', British Journal of Clinical Pharmacology, pp. 246 - 246
1996
Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV, Quick reference:drug interactions. Common drug interactions in HIV medicine', Medical Journal of Australia, vol. 164, pp. 605 - 606
1996
Brooks PM; Day RO, 1995, 'Toxicity of antirheumatic drugs. Toxicity Workgroup Leaders.', J Rheumatol, vol. 22, pp. 998 - 999, https://www.ncbi.nlm.nih.gov/pubmed/8587098
1995
Conaghan PG; Quinn DI; Brooks PM; Day RO, 1995, 'Hazards of low dose methotrexate', Australian and New Zealand Journal of Medicine, vol. 25, pp. 670 - 673, http://dx.doi.org/10.1111/j.1445-5994.1995.tb02851.x
1995
Johnson AG; Quinn DE; Day RO, 1995, 'Non-steroidal anti-inflammatory drugs', Medical Journal of Australia, vol. 163, pp. 155 - 158, http://dx.doi.org/10.1136/bmj.f3195
1995
Johnson AG; Quinn DI; Day RO, 1995, 'Non-steroidal anti-inflammatory drugs', Medical Journal of Australia, vol. 163, pp. 155 - 158
1995
JOHNSON AG; NGUYEN TV; DAY RO, 1995, 'NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND HIGH BLOOD-PRESSURE - RESPONSE', ANNALS OF INTERNAL MEDICINE, vol. 122, pp. 397 - 397, http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00028
1995
Brooks PM; Day R, 1995, 'Treatment issues', Bailliere's Clinical Rheumatology, vol. 9, pp. 231 - 245, http://dx.doi.org/10.1016/S0950-3579(05)80158-X
1995
Quinn DE; Day RO, 1995, 'Drug interactions of clinical importance: an updated guide', Drug Safety, vol. 12, pp. 393 - 452, http://dx.doi.org/10.2165/00002018-199512060-00005
1995
Handel ML; Watts CKW; DeFazio A; Day RO; Sutherland RL, 1995, 'Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos', Proceedings of the National Academy of Sciences of the United States of America, vol. 92, pp. 4497 - 4501, http://dx.doi.org/10.1073/pnas.92.10.4497
1995
Day RO; Francis H; Vial J; Geisslinger G; Williams KM, 1995, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations', Journal of Rheumatology, vol. 22, pp. 2295 - 2303
1995
BOERS M; BROOKS P; TUGWELL P; BAKER P; BOMBARDIER C; DAY R; DRUMMOND M; VANDERLINDEN S; OBRIEN B; SILMAN A; STRAND V; WELLS G, 1995, 'OUTCOME MEASURES IN RHEUMATOID-ARTHRITIS CLINICAL-TRIALS - ACKNOWLEDGMENTS', JOURNAL OF RHEUMATOLOGY, vol. 22, pp. 1433 - 1433, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995RG24600046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1995
Brooks PM; Day RO, 1995, 'Workshop report - Part 1: Toxicity of antirheumatic drugs', Journal of Rheumatology, vol. 22, pp. 998 - 999
1995
Day RO; Francis H; Vial JH; Geisslinger G; Williams KM, 1995, 'Pharmacokinetics and pharmacodynamics of naproxen in synovial fluid and plasma', Journal of Rheumatology, pp. 2295 - 2303
1995
Quinn DE; Day RO, 1995, 'Clinically Important Drug Interactions.', Drug Safety, vol. 12, pp. 393 - 452
1995
Radack K; Johnson AG; Nguyen TV; Day RO, 1995, 'Nonsteroidal anti-inflammatory drugs and high blood pressure [8]', Annals of Internal Medicine, vol. 122, pp. 397, http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00027
1995
Day RO; Geisslinger G; Paull P; Williams KM, 1995, 'The effect of tenoxicam on tolbutamide pharmacokinetics and glucose concentrations in healthy volunteers', International journal of clinical pharmacology, vol. 33, pp. 308 - 310
1995
Brooks PM; Day R, 1995, 'Tropical rheumatology. Treatment issues.', Baillieres Clin Rheumatol, vol. 9, pp. 231 - 245, http://dx.doi.org/10.1016/s0950-3579(05)80158-x
1995
Day RO; Quinn DE; Conaghan PG; Tett S, 1995, 'Adverse drug reactions and their measurement in the rheumatic diseases', Journal of Rheumatology, vol. 22, pp. 983 - 988
1995
McLachlan AJ; Tett SE; Cutler DJ; Day RO, 1994, 'Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate', Chirality, vol. 6, pp. 360 - 364, http://dx.doi.org/10.1002/chir.530060421
1994
Day RO; Birkett DJ; Hicks M; Miners JO; Graham GG; Brooks PM, 1994, 'New Uses for Allopurinol', Drugs, vol. 48, pp. 339 - 344, http://dx.doi.org/10.2165/00003495-199448030-00002
1994
Day R, 1994, 'Meeting report: Asian conference on clinical pharmacology and therapeutics', British Journal of Clinical Pharmacology, vol. 38, pp. 197 - 198
1994
Conaghan PG; Day RO, 1994, 'Risks and Benefits of Drugs Used in the Management and Prevention of Gout', Drug Safety, vol. 11, pp. 252 - 258, http://dx.doi.org/10.2165/00002018-199411040-00004
1994
Parnham MJ; Day RO; van den Berg WB, 1994, 'Inflammation '93', Agents and Actions, vol. 41, http://dx.doi.org/10.1007/BF01987616
1994
Day R; Quinn D, 1994, 'Adverse Interaction Between Warfarin and Indomethacin', Drug Safety, vol. 11, pp. 213 - 214, http://dx.doi.org/10.2165/00002018-199411030-00006
1994
Johnson AG; Seidemann P; Day RO, 1994, 'NSAID-related adverse drug interactions with clinical relevance. An update', International Journal of Clinical Pharmacology and Therapeutics, vol. 32, pp. 509 - 532
1994
LAU ATS; GRAHAM GG; DAY RO; PERRY MA, 1994, 'EFFECT OF HCL CONCENTRATION ON GASTRIC BLOOD-FLOW IN ACUTE ASPIRIN-INDUCED GASTRIC-ULCERS IN THE CAT', GASTROENTEROLOGY, vol. 106, pp. A123 - A123, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994NH90900484&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1994
Day R; Geisslinger G; Paull P; Williams K, 1994, 'Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.', British Journal of Clinical Pharmacology, vol. 37, pp. 79 - 81, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04244.x
1994
Walker J; Nguyen T; Day R, 1994, 'Clinical response to non‐steroidal anti‐inflammatory drugs in urate‐ crystal induced inflammation: a simultaneous study of intersubject and intrasubject variability.', British Journal of Clinical Pharmacology, vol. 38, pp. 341 - 347, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04364.x
1994
Seideman P; Lohrer F; Graham G; Duncan M; Williams K; Day R, 1994, 'The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid.', British Journal of Clinical Pharmacology, vol. 38, pp. 221 - 227, http://dx.doi.org/10.1111/j.1365-2125.1994.tb04345.x
1994
Mclachlan AJ; Tett SE; Cutler DJ; Day RO, 1994, 'Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis', Rheumatology, vol. 33, pp. 235 - 239, http://dx.doi.org/10.1093/rheumatology/33.3.235
1994
Day R; Wodak A; Chesher G, 1994, 'Cannabis and suicide [3]', Medical Journal of Australia, vol. 160, pp. 731
1994
Johnson AG; Nguyen TV; Day RO, 1994, 'Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis', Annals of Internal Medicine, vol. 121, pp. 289 - 300
1994
Tett SE; McLachlan AJ; Cutler DJ; Day RO, 1994, 'Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate', Chirality, vol. 6, pp. 355 - 359, http://dx.doi.org/10.1002/chir.530060420
1994
Johnson AG; Nuygen TV; Day RO, 1994, 'Evaluation of the accuracy and reproducibility of ambulatory blood pressure monitoring in the very elderly using the Takeda TM-2420', Journal of Human Hypertension, vol. 8, pp. 433 - 439
1994
Hicks M; Wong LS; Day RO, 1993, 'Identification of products from oxidation of uric acid induced by hydroxyl radicals', Free Radical Research, vol. 18, pp. 337 - 351, http://dx.doi.org/10.3109/10715769309147501
1993
Day RO, 1993, 'Variability in response to NSAIDs: What progress?', Agents and Actions, vol. 44, pp. 3 - 6
1993
McLachlan A; Tett S; Day R; Cutler D, 1993, 'Interpretation of chloroquine pharmacokinetic data', European Journal of Clinical Pharmacology, vol. 44, pp. 407 - 408, http://dx.doi.org/10.1007/BF00316484
1993
Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Third World conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992.', Agents and actions, vol. 38
1993
Kot TV; Day RO; Brooks PM, 1993, 'Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?', Medical Journal of Australia, vol. 159, pp. 182 - 184
1993
Johnson AG; Seideman P; Day RO, 1993, 'Adverse Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Recognition, Management and Avoidance', Drug Safety, vol. 8, pp. 99 - 127, http://dx.doi.org/10.2165/00002018-199308020-00002
1993
Walker JS; Knihinicki RD; Seideman P; Day RO, 1993, 'Pharmacokinetics of ibuprofen enantiomers in plasma and suction blister fluid in healthy volunteers', Journal of Pharmaceutical Sciences, vol. 82, pp. 787 - 790, http://dx.doi.org/10.1002/jps.2600820806
1993
Handel ML; Sivertsen S; Watts CKW; Day RO; Sutherland RL, 1993, 'Comparative effects of gold on the interactions of transcription factors with DNA', Agents and Actions, vol. 44, pp. 219 - 223
1993
Tett SE; Day RO; Cutler DJ, 1993, 'Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis - A cross sectional study', Journal of Rheumatology, vol. 20, pp. 1874 - 1879
1993
McLachlan A; Tett S; Cutler D; Day R, 1993, 'Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.', British Journal of Clinical Pharmacology, vol. 36, pp. 78 - 81, http://dx.doi.org/10.1111/j.1365-2125.1993.tb05897.x
1993
Diamond HS; Fitzgerald LL; Day R, 1993, 'An analysis of the cost and revenue of an expanded medical residency', Journal of General Internal Medicine, vol. 8, pp. 614 - 618, http://dx.doi.org/10.1007/BF02599717
1993
DAY RO; NGUYEN T; WILLIAMS KM, 1993, 'TENOXICAM DOSE CONCENTRATION RESPONSE RELATIONSHIP IN RHEUMATOID-ARTHRITIS (RA)', CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 53, pp. 152 - 152, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993KP26900067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1993
Day RO; Brooks PM; Williams KM; Graham GG, 1993, 'Meeting report: Third world conference on variability in response to anti-rheumatic drugs, Singapore, July 22-24, 1992', Agents and Actions, vol. 38
1993
WALKER JS; ARROYO JF; NGUYEN T; DAY RO, 1993, 'Analgesic efficacy of non‐steroidal anti‐inflammatory drugs in experimental pain in humans', British Journal of Clinical Pharmacology, vol. 36, pp. 417 - 425, http://dx.doi.org/10.1111/j.1365-2125.1993.tb00390.x
1993
Williams KM; Day RO; Breit SN, 1993, 'Biochemical actions and clinical pharmacology of anti-inflammatory drugs', Advances in Drug Research, vol. 24, pp. 121 - 198
1993
McLACHLAN AJ; TETT SE; CUTLER DJ; DAY RO, 1993, 'Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques', British Journal of Clinical Pharmacology, vol. 36, pp. 405 - 411, http://dx.doi.org/10.1111/j.1365-2125.1993.tb00388.x
1993
Day RO; Wacher T; Cairns D; Conners G; Mcgrath M, 1993, 'Nailfold capillary circulation in osteoarthritis', Rheumatology, vol. 32, pp. 1062 - 1065, http://dx.doi.org/10.1093/rheumatology/32.12.1062
1993
Hicks M; Wong LS; Day RO, 1993, 'Suitability of reverse-phase columns from different sources for separation of uric acid from its oxidation products', Analytical Biochemistry, vol. 210, pp. 428 - 430, http://dx.doi.org/10.1006/abio.1993.1221
1993
Tett SE; Day RO; Lauchlan R, 1993, 'Clinical pharmacy and clinical pharmacology', Australian Journal of Hospital Pharmacy, vol. 23, pp. 207 - 210
1993
Brooks PM; Day RO; Graham GG; Williams KM, 1993, 'Preface', Agents and Actions, vol. 44
1993
Tett S; McLachlan A; Day R; Cutler D, 1993, 'Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine', Agents and Actions, vol. 44, pp. 145 - 150
1993
Carey DL; Day RO; Cairns DR; Pearce GA; Wodak AD; Lauchlan RL, 1992, 'An attempt to influence hypnotic and sedative drug use', Medical Journal of Australia, vol. 156, pp. 389 - 392+396
1992
Steadman CJ; Day RO; Henry DA; Muirden KD; Yeomans ND; Brooks PM; Stiel D; Prichard PJ, 1992, 'Prophylaxis against NSAID-induced ulcers', Medical Journal of Australia, vol. 157, pp. 801 - 803
1992
Zhao B; Geisslinger G; Hall I; Day RO; Williams KM, 1992, 'The effect of the enantiomers of ibuprofen and flurbiprofen on the β‐oxidation of palmitate in the rat', Chirality, vol. 4, pp. 137 - 141, http://dx.doi.org/10.1002/chir.530040302
1992
Lau ATS; Graham GG; Day RO; Perry MA, 1992, 'Effect of aspirin on ulcer site blood flow in cat stomachs', American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 263
1992
Leibbrandt DM; Day RO; Armour C; Clowes C; Day R; Deans K; Eckert G; Gridneff G; Hampson J; Henry D; Higgins G; Hobbes J; Johnson G; Kaye K; Kelly M; Kirkwood L; Lauchlan R; Liebbrandt D; McDougall A, 1992, 'Cyclosporin and calcium channel blockers: An exploitable drug interaction?', Medical Journal of Australia, vol. 157, pp. 296 - 297
1992
LAU ATS; GRAHAM GG; DAY RO; PERRY MA, 1992, 'EFFECT OF ASPIRIN ON ULCER SITE BLOOD-FLOW IN CAT STOMACHS', AMERICAN JOURNAL OF PHYSIOLOGY, vol. 263, pp. G155 - G160, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992JJ95800072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1992
Tett SE; Cutler DJ; Day RO, 1992, 'Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques', Journal of Pharmaceutical Sciences, vol. 81, pp. 155 - 159, http://dx.doi.org/10.1002/jps.2600810211
1992
Sandhu GS; Day RO, 1992, 'Factors affecting prescribing in general practice - A role play', Medical Journal of Australia, vol. 157, pp. 621 - 622
1992
EBRINGER R; AHERN M; THOMAS D; GRIFFITHS H; OCALLAGHAN J; LITTLEJOHN G; LEWIS D; HAZELTON R; BARRACLOUGH D; STOCKMAN A; TRAVERS R; GLASS J; MAJOR G; RATNARAJAH S; BROOKS P; CARR G; LAURENT R; MCNAUGHT P; NEEDS C; POTTER S; SCHRIEBER L; DEJAGER J; JOHNSON F; PORTEK I; BROWN C; DAY R; SAMBROOK P; BROOK A; TYMMS K; CAIRNS D, 1992, 'SULFASALAZINE IN EARLY RHEUMATOID-ARTHRITIS - THE AUSTRALIAN MULTICENTER CLINICAL-TRIAL GROUP', JOURNAL OF RHEUMATOLOGY, vol. 19, pp. 1672 - 1677, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992JY69000005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1992
Lau AT; Graham GG; Day RO; Perry MA, 1992, 'Effect of aspirin on ulcer site blood flow in cat stomachs.', Am J Physiol, vol. 263, pp. G155 - G160, http://dx.doi.org/10.1152/ajpgi.1992.263.2.G155
1992
Hicks M; Wong LS; Day RO, 1992, 'Antioxid ant activity of propylthiouracil', Biochemical Pharmacology, vol. 43, pp. 439 - 444, http://dx.doi.org/10.1016/0006-2952(92)90561-V
1992
Day RO; Henry DA; Muirden KD; Yeomans ND; Brooks PM; Stiel D; Prichard PJ, 1992, 'Non-steroidal anti-inflammatory drug induced upper gastrointestinal haemorrhage and bleeding', Medical Journal of Australia, vol. 157, pp. 810 - 812
1992
STUARTHARRIS RC; LAUCHLAN R; DAY R, 1992, 'THE CLINICAL-APPLICATION OF THE INTERFERONS - A REVIEW', MEDICAL JOURNAL OF AUSTRALIA, vol. 156, pp. 869 - 872, http://dx.doi.org/10.5694/j.1326-5377.1992.tb137004.x
1992
Winn JS; Guille J; Gebicki JM; Day RO, 1991, 'Hydrogen peroxide modulation of the respiratory burst of human neutrophils', Biochemical Pharmacology, vol. 41, pp. 31 - 36, http://dx.doi.org/10.1016/0006-2952(91)90007-R
1991
Kino R; Day RO; Pearce GA; Fulde GWO, 1991, 'Bedside measurement of plasma theophylline concentration within the emergency department', Australian Journal of Hospital Pharmacy, vol. 21, pp. 292 - 294
1991
Birkett D; Miners J; Day R, 1991, '1‐Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.', British Journal of Clinical Pharmacology, vol. 32, pp. 238 - 241, http://dx.doi.org/10.1111/j.1365-2125.1991.tb03888.x
1991
Füger KE; Wienbeck M; Mann J; Kornowski R; Aderka D; Schwartz D; Levo Y; Djahanguiri B; Brooks P; Day RO, 1991, 'Nonsteroidal antiinflammatory drugs — differences and similarities', New England Journal of Medicine, vol. 325, pp. 1653 - 1654, http://dx.doi.org/10.1056/NEJM199112053252314
1991
Johnson AG; Day RO, 1991, 'The Problems and Pitfalls of NSAID Therapy in the Elderly (Part II)', Drugs & Aging, vol. 1, pp. 212 - 227, http://dx.doi.org/10.2165/00002512-199101030-00005
1991
Johnson AG; Day RO, 1991, 'The Problems and Pitfalls of NSAID Therapy in the Elderly (Part I)', Drugs & Aging, vol. 1, pp. 130 - 143, http://dx.doi.org/10.2165/00002512-199101020-00005
1991
FUGER KE; WIENBECK M; MANN J, 1991, 'NONSTEROIDAL ANTIINFLAMMATORY DRUGS - DIFFERENCES AND SIMILARITIES', NEW ENGLAND JOURNAL OF MEDICINE, vol. 325, pp. 1653 - 1653, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1991GR77000013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1991
Kino R; Day RO; Pearce GA; Fulde GWO, 1991, 'Aminophylline in the emergency department: Maximizing safety and efficacy', Chest, vol. 100, pp. 1572 - 1577, http://dx.doi.org/10.1378/chest.100.6.1572
1991
Day R; Seideman P, 1991, 'NSAIDs, musculoskeletal disorders and gastrointestinal adverse effects.', Australian family physician, vol. 20, pp. 1735 - 1737
1991
Brooks PM; Day RO, 1991, 'Nonsteroidal Antiinflammatory Drugs — Differences and Similarities', New England Journal of Medicine, vol. 324, pp. 1716 - 1725, http://dx.doi.org/10.1056/NEJM199106133242407
1991
Day RO; Williams KM; Graham S; Handel M, 1991, 'The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma', Arthritis & Rheumatism, vol. 34, pp. 751 - 760, http://dx.doi.org/10.1002/art.1780340617
1991
Handel ML; deFazio A; Watts CKW; Day RO; Sutherland RL, 1991, 'Inhibition of DNA binding and transcriptional activity of a nuclear receptor transcription factor by aurothiomalate and other metal ions', Molecular Pharmacology, vol. 40, pp. 613 - 618
1991
Knihinicki RD; Day RO; Williams KM, 1991, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-II Racemization and hydrolysis of (R)- and (S)-ibuprofen-CoA thioesters', Biochemical Pharmacology, vol. 42, pp. 1905 - 1911, http://dx.doi.org/10.1016/0006-2952(91)90588-V
1991
Williams KM; Knihinicki RD; Day RO, 1991, 'Pharmacokinetics of the enantiomers of ibuprofen in the rabbit', Agents and Actions, vol. 34, pp. 381 - 386, http://dx.doi.org/10.1007/BF01988732
1991
Joyce DA; Day RO; Murphy BR, 1991, 'The pharmacokinetics of albumin conjugates of D-penicillamine in humans', Drug Metabolism and Disposition, vol. 19, pp. 309 - 311
1991
Nuernberg B; Knihinicki R; Williams K; Freeman GE; Dalton C; Brooks PM; Day RO, 1990, 'Anti-inflammatory effects and disposition of S- and R-flurbiprofen in the rat', European Journal of Pharmacology, vol. 183, pp. 1591 - 1592, http://dx.doi.org/10.1016/0014-2999(90)94757-O
1990
Knihinicki RD; Day RO; Graham GG; Williams KM, 1990, 'Stereoselective disposition of ibuprofen and flurbiprofen in rats', Chirality, vol. 2, pp. 134 - 140, http://dx.doi.org/10.1002/chir.530020303
1990
Joyce D; Day R, 1990, 'D‐penicillamine and D‐penicillamine‐protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.', British Journal of Clinical Pharmacology, vol. 30, pp. 511 - 517, http://dx.doi.org/10.1111/j.1365-2125.1990.tb03808.x
1990
Tett S; Cutler D; Day R, 1990, 'Antimalarials in rheumatic diseases', Bailliere's Clinical Rheumatology, vol. 4, pp. 467 - 489, http://dx.doi.org/10.1016/S0950-3579(05)80004-4
1990
Tett SE; Cutler DJ; Day RO, 1990, 'Hydroxychloroquine concentrations and clinical effects in rheumatoid arthritis patients', European Journal of Pharmacology, vol. 183, pp. 1035, http://dx.doi.org/10.1016/0014-2999(90)92892-M
1990
Johnson AG; Day RO; Seldon WA, 1990, 'A functional psychosis precipitated by quinidine', Medical Journal of Australia, vol. 153, pp. 47 - 49
1990
Pearce GA; Day RO, 1990, 'Compliance with criteria necessary for effective drug concentration monitoring', Therapeutic Drug Monitoring, vol. 12, pp. 250 - 257, http://dx.doi.org/10.1097/00007691-199005000-00007
1990
Day R, 1989, 'Trends in the treatment of rheumatoid arthritis: Australia', Rheumatology SEAPAL 1988: proceedings of the 6th SEAPAL Congress of rheumatology. ICS809, pp. 159 - 161
1989
Sambrook PN; Champion GD; Browne CD; Cairns D; Cohen ML; Day RO; Graham S; Handel M; Jaworski R; Kempler S; Wach er T, 1989, 'Corticosteroid injection for osteoarthritis of the knee: Peripatellar compared to intra-articular route', Clinical and Experimental Rheumatology, vol. 7, pp. 609 - 613
1989
HO KY; WEISSBERGER AJ; STUART MC; DAY RO; LAZARUS L, 1989, 'THE PHARMACOKINETICS, SAFETY AND ENDOCRINE EFFECTS OF AUTHENTIC BIOSYNTHETIC HUMAN GROWTH HORMONE IN NORMAL SUBJECTS', Clinical Endocrinology, vol. 30, pp. 335 - 345, http://dx.doi.org/10.1111/j.1365-2265.1989.tb00431.x
1989
Knihinicki RD; Williams KM; Day RO, 1989, 'Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs-1. In vitro studies of ibuprofen and flurbiprofen', Biochemical Pharmacology, vol. 38, pp. 4389 - 4395, http://dx.doi.org/10.1016/0006-2952(89)90647-3
1989
Tett S; Cutler D; Day R; Brown K, 1989, 'Bioavailability of hydroxychloroquine tablets in healthy volunteers.', British Journal of Clinical Pharmacology, vol. 27, pp. 771 - 779, http://dx.doi.org/10.1111/j.1365-2125.1989.tb03439.x
1989
Day R; Graham G; Bieri D; Brown M; Cairns D; Harris G; Hounsell J; Platt‐ Hepworth S; Reeve R; Sambrook P; et al , 1989, 'Concentration‐response relationships for salicylate‐induced ototoxicity in normal volunteers.', British Journal of Clinical Pharmacology, vol. 28, pp. 695 - 702, http://dx.doi.org/10.1111/j.1365-2125.1989.tb03562.x
1989
Graham SR; Day RO; Hardy M, 1989, 'Captopril overdose', Medical Journal of Australia, vol. 151, pp. 111
1989
Day RO; Furst DE; Dromgoole SH; Paulus HE, 1988, 'Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers', Biopharmaceutics & Drug Disposition, vol. 9, pp. 273 - 283, http://dx.doi.org/10.1002/bod.2510090306
1988
Day RO, 1988, 'Mode of action of non-steroidal anti-inflammatory drugs', Medical Journal of Australia, vol. 148, pp. 195 - 199
1988
Bowden GJ; Cadogan JM; Day RK; Dunlop JB, 1988, '169Tm Mössbauer experiments in the paramagnetic phase of Tm2 Al', Hyperfine Interactions, vol. 39, pp. 359 - 367, http://dx.doi.org/10.1007/BF02397645
1988
Keogh A; Day R; Critchley L; Duggin G; Baron D, 1988, 'The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients', Transplantation Proceedings, vol. 20, pp. 27 - 30
1988
Stewart GA; Day RK; Dunlop JB; Price DC, 1988, 'A two-site analysis of169Tm Mössbauer measurements on thulium sesquioxide', Hyperfine Interactions, vol. 40, pp. 339 - 342, http://dx.doi.org/10.1007/BF02049112
1988
Day R; Miners J; Birkett D; Graham G; Whitehead A, 1988, 'Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.', British Journal of Clinical Pharmacology, vol. 26, pp. 429 - 434, http://dx.doi.org/10.1111/j.1365-2125.1988.tb03402.x
1988
Graham SR; Day RO; Lee R; Fulde GWO, 1988, 'Overdose with chloral hydrate: A pharmacological and therapeutic review', Medical Journal of Australia, vol. 149, pp. 686 - 688
1988
Day R; Paull P; Lam S; Swanson B; Williams K; Wade D, 1988, 'The effect of concurrent aspirin upon plasma concentrations of tenoxicam.', British Journal of Clinical Pharmacology, vol. 26, pp. 455 - 462, http://dx.doi.org/10.1111/j.1365-2125.1988.tb03405.x
1988
Day R; Harris G; Brown M; Graham G; Champion G, 1988, 'Interaction of salicylate and corticosteroids in man.', British Journal of Clinical Pharmacology, vol. 26, pp. 334 - 337, http://dx.doi.org/10.1111/j.1365-2125.1988.tb05286.x
1988
Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; De Jager J; Sambrook PN, 1988, 'Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis', Journal of Rheumatology, vol. 15, pp. 28 - 34
1988
Day R; Miners J; Birkett D; Whitehead A; Naidoo D; Hayes J; Savdie E, 1988, 'Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.', British Journal of Clinical Pharmacology, vol. 26, pp. 423 - 428, http://dx.doi.org/10.1111/j.1365-2125.1988.tb03401.x
1988
Day RO; Breit SN; Cairns D; Champion GD, 1988, 'Aspects of the clinical trials of slow-acting anti-rheumatic drugs.', Agents and actions. Supplements, vol. 24, pp. 121 - 133
1988
Williams KM; Day RO, 1988, 'The contribution of enantiomers to variability in response to anti-inflammatory drugs.', Agents and actions. Supplements, vol. 24, pp. 76 - 84
1988
Day RO; Williams KM; Graham GG; Lee EJ; Knihinicki RD; Champion GD, 1988, 'Stereoselective disposition of ibuprofen enantiomers in synovial fluid', Clinical Pharmacology and Therapeutics, vol. 43, pp. 480 - 487, http://dx.doi.org/10.1038/clpt.1988.62
1988
Day RO; Graham GG; Williams KM, 1988, 'Pharmacokinetics of non-steroidal anti-inflammatory drugs', Bailliere's Clinical Rheumatology, vol. 2, pp. 363 - 393, http://dx.doi.org/10.1016/S0950-3579(88)80019-0
1988
Tett S; Cutler D; Day R; Brown K, 1988, 'A dose‐ranging study of the pharmacokinetics of hydroxy‐chloroquine following intravenous administration to healthy volunteers.', British Journal of Clinical Pharmacology, vol. 26, pp. 303 - 313, http://dx.doi.org/10.1111/j.1365-2125.1988.tb05281.x
1988
Day RO; Graham GG; Willia KM; Brooks PM, 1988, 'Variability in Response to NSAIDs: Fact or Fiction?', Drugs, vol. 36, pp. 643 - 651, http://dx.doi.org/10.2165/00003495-198836060-00001
1988
Patapanian H; Graham S; Sambrook PN; Browne CD; Champion GD; Cohen ML; Day RO, 1988, 'The oncogenicity of chlorambucil in rheumatoid arthritis', Rheumatology, vol. 27, pp. 44 - 47, http://dx.doi.org/10.1093/rheumatology/27.1.44
1988
Day RO; Graham GG; Williams KM; David Champion G; de Jager J, 1987, 'Clinical pharmacology of non-steroidal anti-inflammatory drugs', Pharmacology and Therapeutics, vol. 33, pp. 383 - 433, http://dx.doi.org/10.1016/0163-7258(87)90072-6
1987
PATAPANIAN H; SAMBROOK PN; BROWNE CD; CHAMPION GD; DAY RO; COHEN ML, 1987, 'ONCHOGENICITY OF CHLORAMBUCIL IN RHEUMATOID-ARTHRITIS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 17, pp. 124 - 124, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1987G353300058&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1987
Reilly DK; Ray JE; Day RO; Wodak A; O'Connor D; Thompson J, 1987, 'Classification of overdose/self-poisoning presentations to an accident and emergency department', International Journal of the Addictions, vol. 22, pp. 941 - 955
1987
Reilly DK; Ray JE; Day RO; Wodak A; Bsocstud DOC; Thompson J, 1987, 'Classification of overdose/self-poisoning presentations to an accident and emergency department', Substance Use and Misuse, vol. 22, pp. 941 - 955, http://dx.doi.org/10.3109/10826088709109691
1987
WING LMH; MOULDS RFW; SHENFIELD GM; DAY RO, 1987, 'DRUG ADVERTISING - REPLY', MEDICAL JOURNAL OF AUSTRALIA, vol. 147, pp. 361 - 361, http://dx.doi.org/10.5694/j.1326-5377.1987.tb133532.x
1987
Mant A; Wodak A; Day R, 1987, 'Benzodiazepine dependence. Strategies for prevention and withdrawal', Current Therapeutics, vol. 28, pp. 59 - 79
1987
Day R; Brooks P, 1987, 'Variations in response to non‐steroidal anti‐inflammatory drugs.', British Journal of Clinical Pharmacology, vol. 23, pp. 655 - 658, http://dx.doi.org/10.1111/j.1365-2125.1987.tb03098.x
1987
MOULDS RFW; DAY RO, 1987, 'DRUG ADVERTISING', MEDICAL JOURNAL OF AUSTRALIA, vol. 147, pp. 52 - 52, http://dx.doi.org/10.5694/j.1326-5377.1987.tb133252.x
1987
Day R; Lam S; Paull P; Wade D, 1987, 'Effect of food and various antacids on the absorption of tenoxicam.', British Journal of Clinical Pharmacology, vol. 24, pp. 323 - 328, http://dx.doi.org/10.1111/j.1365-2125.1987.tb03176.x
1987
WILLIAMS KM; DAY RO; KNIHINICKI RD; DUFFIELD AM, 1986, 'STEREOSELECTIVE INCORPORATION OF IBUPROFEN ENANTIOMERS INTO ADIPOSE-TISSUE IN RATS AND MAN', ACTA PHARMACOLOGICA ET TOXICOLOGICA, vol. 59, pp. 192 - 192, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1986D896000552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1986
Davis A; Day RO; Begg EJ, 1986, 'INTERACTIONS BETWEEN NON‐STEROIDAL ANTI‐INFLAMMATORY DRUGS AND ANTIHYPERTENSIVES AND DIURETICS', Australian and New Zealand Journal of Medicine, vol. 16, pp. 537 - 546, http://dx.doi.org/10.1111/j.1445-5994.1986.tb02031.x
1986
Ray JE; Reilly DK; Day RO, 1986, 'Drugs involved in self-poisoning: Verification by toxicological analysis', Medical Journal of Australia, vol. 144, pp. 455 - 457
1986
Goadsby PJ; Day RO; Kwan YL; Miners J; Birkett DJ, 1986, '6-MERCAPTOPURINE-RELATED LEUCOPENIA AND IN VIVO XANTHINE OXIDASE ACTIVITY', The Lancet, vol. 328, pp. 869 - 870, http://dx.doi.org/10.1016/S0140-6736(86)92911-9
1986
Sambrook PN; Champion GD; Browne CD; Cohen ML; Compton P; Day RO; Jager JD, 1986, 'Comparison of methotrexate with azathioprine or 6-mercaptopurine in refractory rheumatoid arthritis: A life-table analysis', Rheumatology, vol. 25, pp. 372 - 375, http://dx.doi.org/10.1093/rheumatology/25.4.372
1986
Williams K; Day R; Knihinicki R; Duffield A, 1986, 'The stereoselective uptake of ibuprofen enantiomers into adipose tissue', Biochemical Pharmacology, vol. 35, pp. 3403 - 3405, http://dx.doi.org/10.1016/0006-2952(86)90443-0
1986
SAMBROOK PN; CHAMPION GD; COMPTON PJ; BROWNE CD; COHEN M; DAY RO; DEJAGER JP, 1986, 'THERAPEUTIC OUTCOME WITH METHOTREXATE AND AZATHIOPRINE IN RHEUMATOID-ARTHRITIS - A LIFE TABLE ANALYSIS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 16, pp. 144 - 144, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1986A500500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1986
Lee E; Williams K; Day R; Graham G; Champion D, 1985, 'Stereoselective disposition of ibuprofen enantiomers in man.', British Journal of Clinical Pharmacology, vol. 19, pp. 669 - 674, http://dx.doi.org/10.1111/j.1365-2125.1985.tb02694.x
1985
Williams KM; Day RO, 1985, 'Stereoselective disposition--basis for variability in response to NSAID's.', Agents and actions. Supplements, vol. 17, pp. 119 - 126
1985
DAY RO; WILLIAMS KM; LEE EJ; KNIHINICKI R, 1985, 'DISPOSITION OF ENANTIOMERS OF IBUPROFEN IN PLASMA AND SYNOVIAL-FLUID IN ARTHRITIC DISEASE', CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, vol. 8, pp. A58 - A58, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1985AQS8500134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1985
Day RO, 1985, 'Variability in response to NSAID.', Agents and actions. Supplements, vol. 17, pp. 15 - 19
1985
Ray JD; Day RO, 1984, 'High-performance liquid chromatographic determination of a new anti-inflammatory agent, nabumetone, and its major metabolite in plasma using fluorimetric detection', Journal of Chromatography B: Biomedical Sciences and Applications, vol. 336, pp. 234 - 239, http://dx.doi.org/10.1016/S0378-4347(00)85146-4
1984
Graham GG; Day RO; Champion GD; Lee E; Newton K, 1984, 'Aspects of the clinical pharmacology of non-steroidal anti- inflammatory drugs', Clinics in Rheumatic Diseases, vol. 10, pp. 229 - 249
1984
Lee EJD; Williams KM; Graham GG; Day RO; Champion GD, 1984, 'Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans', Journal of Pharmaceutical Sciences, vol. 73, pp. 1542 - 1544, http://dx.doi.org/10.1002/jps.2600731112
1984
Day RO; Graham GG; Champion GD; Lee E, 1984, 'Anti-rheumatic drug interactions', Clinics in Rheumatic Diseases, vol. 10, pp. 251 - 275
1984
McGirr EE; Browne CD; Champion GD; Day RO; Sambrook PN, 1984, 'Aurothioglucose in rheumatoid arthritis. Outcome of treatment in patients intolerant of sodium aurothiomalate', Medical Journal of Australia, vol. 141, pp. 349 - 351
1984
Day RO; Shen DD; Azarnoff DL, 1983, 'Induction of Salicyluric Acid Formation in Rheumatoid Arthritis Patients Treated with Salicylates', Clinical Pharmacokinetics, vol. 8, pp. 263 - 271, http://dx.doi.org/10.2165/00003088-198308030-00005
1983
Ray JE; Day RO, 1983, 'High‐performance liquid chromatographic analysis of diflunisal in plasma and urine: Application to pharmacokinetic studies in two normal volunteers', Journal of Pharmaceutical Sciences, vol. 72, pp. 1403 - 1405, http://dx.doi.org/10.1002/jps.2600721209
1983
BEGG EJ; CHINWAH PM; WEBB C; DAY RO; WADE DN, 1983, 'INTERACTION OF MEXILETINE WITH PHENYTOIN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 10, pp. 191 - 192, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983QN17900029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1983
RAY JE; REILLY DK; HAAVISTO T; PAULL PD; DAY RO, 1983, 'SURVEY OF DRUG-ABUSE PATTERNS IN A CASUALTY DEPARTMENT POPULATION', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 10, pp. 715 - 716, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RW31100125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1983
DAY RO; HARRIS G; BROWN M; GRAHAM G, 1983, 'ASPIRIN GLUCOCORTICOSTEROID INTERACTION IN MAN', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 10, pp. 717 - 717, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RW31100128&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1983
Day RO; Sambrook P; Champion GD; Graham GG, 1982, 'Antimalarials in rheumatic diseases', Australian and New Zealand Journal of Medicine, vol. 12, pp. 645 - 649, http://dx.doi.org/10.1111/j.1445-5994.1982.tb02658.x
1982
HARRIS G; CAIRNS D; BIERI D; CHAMPION D; DAY R; GRAHAM G, 1982, 'RESPONSE OF RHEUMATOID-ARTHRITIS TO SLOWLY ACTING ANTI-RHEUMATIC DRUGS', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 12, pp. 561 - 561, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PN87700060&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1982
Begg E; Chinwah P; Webb C; Day R; Wade D, 1982, 'Enhanced metabolism of mexiletine after phenytoin administration.', British Journal of Clinical Pharmacology, vol. 14, pp. 219 - 223, http://dx.doi.org/10.1111/j.1365-2125.1982.tb01965.x
1982
RAY JE; DAY RO, 1982, 'DIFLUNISAL, A SPECIFIC ANALYTICAL PROCEDURE AND PRELIMINARY PHARMACOKINETICS IN MAN', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 12, pp. 572 - 572, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PN87700093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1982
CHAMPION GD; BIERI D; BROWNE CD; DAY RO; GRAHAM GG; HAAVISTO TM; SAMBROOK PN; VALLANCE JB, 1982, 'AURANOFIN IN RHEUMATOID-ARTHRITIS', JOURNAL OF RHEUMATOLOGY, vol. 9, pp. 137 - 145, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PN15300021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1982
Day RO; Furst DE; Dromgoole SH; Kamm B; Roe R; Paulus HE, 1982, 'Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis', Clinical Pharmacology and Therapeutics, vol. 31, pp. 733 - 740, http://dx.doi.org/10.1038/clpt.1982.103
1982
Sambrook PN; Browne CD; Champion GD; Day RO; Vallance JB; Warwick N, 1982, 'Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis', Journal of Rheumatology, vol. 9, pp. 932 - 934
1982
DAY RO; FURST DE; DROMGOOLE SH; PAULUS HE, 1982, 'DECLINE OF STEADY-STATE SERUM SALICYLIC-ACID CONCENTRATIONS WITH TIME IN NORMAL VOLUNTEERS GIVEN HIGH-DOSE ASPIRIN', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, vol. 12, pp. 557 - 558, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1982PN87700049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1982
Ray JE; Day RO, 1982, 'Diflunisal, a specific analytical procedure and preliminary pharmacokinetics in man', Clinical and Experimental Pharmacology and Physiology, vol. 9, pp. 453
1982
Day RO; Furst DE; Dromgoole SH, 1981, 'Naproxen serum level response relationship in rheumatoid arthritis', Australian and New Zealand Journal of Medicine, vol. 11, pp. 720
1981
Day RO, 1981, 'Effects of exercise performance on drugs used musculoskeletal disorders', Medicine and Science in Sports and Exercise, vol. 13, pp. 272 - 275, http://dx.doi.org/10.1249/00005768-198104000-00013
1981
Furst DE; Day RO; Dromgoole SH, 1981, 'Steady-state serum level vs response relationship for naproxen in rheumatoid arthritis', Clinical Pharmacology and Therapeutics, vol. 29, pp. 247
1981
Day RO; Furst DE; Dromgoole SH, 1981, 'Decline in steady-state serum levels of salicylate in normal subjects: Preliminary results', Clinical and Experimental Pharmacology and Physiology, vol. 8
1981
Day RO; Dromgoole SH; Furst DE; Hignite C; Paulus HE, 1981, 'Formation of methyl ester of salicyluric acid during quantitation of salicyluric acid in urine by high‐pressure liquid chromatography', Journal of Pharmaceutical Sciences, vol. 70, pp. 1090 - 1092, http://dx.doi.org/10.1002/jps.2600700934
1981
Day RO; Pearson CM, 1981, 'Primary inflammatory muscle diseases', Comprehensive Therapy, vol. 7, pp. 22 - 30
1981
Day R; Shen D; Azarnoff D, 1979, 'Decline of steady-state serum salicylate in rheumatoid arthritics given high-dosage salicylate therapy', Clinical Pharmacology and Therapeutics, vol. 25, pp. 220 - 221
1979
Day RO; Shen DD; Azarnoff DL, 1979, 'Effect of high-dosage salicylate therapy on average steady-state serum salicylate and formation of salicylurate in patients with rheumatoid arthritis', Clinical Research, vol. 27
1979
Day RO; Lindsley HB, 1979, 'Rational use of aspirin and nonsteroidal anti-inflammatory drugs in inflammatory arthritis.', The Journal of the Kansas Medical Society, vol. 80, pp. 155 - 159
1979
Graham G; Champion GD; Day RO, 1979, 'The pharmacokinetics of salicyclate in patients with rheumatoid arthritis', Clinical and Experimental Pharmacology and Physiology, vol. 6, pp. 194
1979
Champion GD; Day RO; Paull PD, 1979, 'Clinical pharmacology and efficacy of benorylate in patients with rheumatoid arthritis', Current Therapeutics, vol. 20, pp. 145
1979
RAY JE; WADE DN; GRAHAM GG; DAY RO, 1979, 'Pharmacokinetics of Carprofen in Plasma and Synovial Fluid', The Journal of Clinical Pharmacology, vol. 19, pp. 635 - 643, http://dx.doi.org/10.1002/j.1552-4604.1979.tb01626.x
1979
Day RO, 1979, 'Deafness due to aspirin.', Journal of Clinical Pharmacology, vol. 19, pp. 328
1979
Day RO; Wade DN, 1978, 'Influence of flufenamic acid and calcium ion concentration on the histamine release from rat mast cells induced by compound 48/80 and the calcium ionophore A23187', Biochemical Pharmacology, vol. 27, pp. 1385 - 1387, http://dx.doi.org/10.1016/0006-2952(78)90126-0
1978
Champion GD; Day RO; Paull PD; Graham GG; Owen MS; Haski AL; Hills L, 1978, 'Clinical Pharmacology and Efficacy of Benorylate in Patients with Rheumatoid Arthritis', Australian and New Zealand Journal of Medicine, vol. 8, pp. 22 - 28, http://dx.doi.org/10.1111/j.1445-5994.1978.tb02398.x
1978
Day RO; Champion GD; Wade DN, 1978, 'The effect of various drugs on compound 48/80 and osmotic shock-induced histamine release from rat peritoneal cells', Clinical and Experimental Pharmacology and Physiology, vol. 5, pp. 241 - 242
1978
Day RO; Wade DN, 1978, 'THE EFFECT OF VARIOUS DRUGS ON ADENOSINE TRIPHOSPHATE CONTENT AND HISTAMINE RELEASE FROM RAT PERITONEAL CELL SUSPENSIONS RICH IN MAST CELLS', Clinical and Experimental Pharmacology and Physiology, vol. 5, pp. 223 - 227, http://dx.doi.org/10.1111/j.1440-1681.1978.tb00675.x
1978
Day RO; Wade DN, 1978, 'EFFECTS OF VARIOUS DRUGS ON THE OSMOTIC LYSIS OF RAT MAST CELLS', Clinical and Experimental Pharmacology and Physiology, vol. 5, pp. 477 - 485, http://dx.doi.org/10.1111/j.1440-1681.1978.tb00700.x
1978
Graham G; Champion GD; Day RO; Paull PD, 1977, 'The pharmacokinetics of salicylate in patients with rheumatoid arthritis', Clinical and Experimental Pharmacology and Physiology, vol. 4, pp. 214
1977
Champion GD; Corrigan AB; Day RO, 1977, 'The effect of enteric coating of aspirin tablets on occult gastrointestinal blood loss', Clinical and Experimental Pharmacology and Physiology, vol. 4, pp. 214 - 215
1977
Grahm GG; Champion GD; Day RO, 1977, 'Salicylates in rheumatoid arthritis: Pharmacokinetics and analgesic responses', Agents and Actions, vol. 7, pp. 35 - 42
1977
Graham GG; Champion GD; Day RO; Paull PD, 1977, 'Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis', Clinical Pharmacology and Therapeutics, vol. 22, pp. 410 - 420, http://dx.doi.org/10.1002/cpt1977224410
1977
Graham GG; Champion GD; Day RO; Kaski AL; Hills LG; Paull PD, 1977, 'Salicylates in rheumatoid arthritis: pharmacokinetics and analgesic response.', Agents and Actions Supplements, pp. 37 - 42
1977
Howe GB; Champion GD; Corrigan AB; Hewson J; Haski A; Day RO; Paull PD; Graham GG, 1977, 'The Effects of Enteric Coating of Aspirin Tablets on Occult Gastrointestinal Blood Loss', Australian and New Zealand Journal of Medicine, vol. 7, pp. 600 - 604, http://dx.doi.org/10.1111/j.1445-5994.1977.tb02315.x
1977
Day RO; Ray JE; Champion GD; Wade DN, 1977, 'The effect of non steroidal anti inflammatory drugs on ATP levels and histamine release from rat peritoneal cell suspension rich in mast cells', Clinical and Experimental Pharmacology and Physiology, vol. 4, pp. 212 - 213
1977
Day RK; Bowden GJ, 1977, 'Magnetic anomalies in ErFe3', Physica B+C, vol. 86-88, pp. 71 - 72, http://dx.doi.org/10.1016/0378-4363(77)90230-3
1977
Day RO; Paull PD; Ray JE; Wade DN, 1977, 'The measurement of histamine release from suspensions of rat peritoneal cells rich in mast cells', Agents and Actions, vol. 7, pp. 431 - 436, http://dx.doi.org/10.1007/BF01966848
1977
Bowden GJ; Day RK, 1977, 'A novel low temperature rearrangement of atoms in the rare earth intermetallic compound ErFe3', Journal of Physics F: Metal Physics, vol. 7, pp. 181 - 190, http://dx.doi.org/10.1088/0305-4608/7/1/027
1977
CHAMPION GD; DAY RO; RAY JE; WADE DN, 1977, 'THE EFFECT OF NON‐STEROIDAL ANTI‐INFLAMMATORY DRUGS ON ADENOSINE TRIPHOSPHATE CONTENT AND HISTAMINE RELEASE FROM RAT PERITONEAL CELL SUSPENSIONS RICH IN MAST CELLS', British Journal of Pharmacology, vol. 59, pp. 29 - 33, http://dx.doi.org/10.1111/j.1476-5381.1977.tb06973.x
1977
Bowden GJ; Day RK, 1977, 'On the magnetic anomaly in ErFe3 at 47K', Journal of Physics F: Metal Physics, vol. 7, pp. 191 - 197, http://dx.doi.org/10.1088/0305-4608/7/1/028
1977
Champion GD; Day RO; Fagan N, 1977, 'Single dose comparison of analgesic action of acetylsalicylate and sodium salicylate in rheumatoid arthritis', Clinical and Experimental Pharmacology and Physiology, vol. 4, pp. 213
1977
Day RO; Paull PD; Champion GD; Graham GG, 1976, 'Evaluation of an Enteric Coated Aspirin Preparation', Australian and New Zealand Journal of Medicine, vol. 6, pp. 45 - 50, http://dx.doi.org/10.1111/j.1445-5994.1976.tb03290.x
1976
Crozier RH; Day RW, 1976, 'Niche breadth in Bryozoans', Nature, vol. 260, pp. 77 - 78, http://dx.doi.org/10.1038/260077c0
1976
Paull P; Day R; Graham G; Champion D, 1976, 'Single dose evaluation of a new enteric coated aspirin preparation', Medical Journal of Australia, vol. 1, pp. 617 - 619
1976
Paull PD; Day RO; Graham GG; Champion GD, 1975, 'Bioavailability of enteric coated aspirin', Clinical and Experimental Pharmacology and Physiology, vol. 2, pp. 442
1975
Austin M; Singer G; Day RH, 1969, 'Visual orientation illusion following judgments with a tilted visual field', Nature, vol. 221, pp. 583 - 584, http://dx.doi.org/10.1038/221583a0
1969
Nguyen AD; Frensham LJ; Wong MXC; Meslin SMM; Martin P; Lau AY; Baysari MT; Day RO, 'Patient testing of a mobile health app and review of educational materials designed for gout patient self-management (Preprint)', , http://dx.doi.org/10.2196/preprints.9811
Conference Abstracts
add
Green EAE; Yee SW; Rashkin SR; Witte J; Shin JG; Klovins J; Stocker S; Day R; Giacomini KM, 2019, 'GENETIC DETERMINANTS OF METFORMIN PHARM-ACOKINETICS: A METFORMIN GENETIC CONSORTIUM COLLABORATION.', in CLINICAL PHARMACOLOGY & THERAPEUTICS, WILEY, Washington, DC, Vol. 105, pp. S36 - S36, presented at Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics, Washington, DC, 13 March 2019 - 16 March 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000458561100109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2019
Stocker SL; Carland JE; Moran MA; Tang S; Li CY; Alin JS; Gilbey T; Graham GG; Williams KM; Marriott DJ; Day RO, 2018, 'A CLINICAL EVALUATION OF VANCOMYCIN DOSING AND MONITORING.', in CLINICAL PHARMACOLOGY & THERAPEUTICS, WILEY, Orlando, FL, Vol. 103, pp. S88 - S88, presented at 119th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics (ASCPT) - Breaking Down Barriers to Effective Patient Care, Orlando, FL, 21 March 2018 - 24 March 2018, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424997100316&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2018
Kamel B; Stocker S; Graham G; Carland J; Parker M; Williams K; Pile K; Portek I; McGill N; Day R, 2017, 'A MULTICENTRE OPEN-LABEL PHARMACOKINETIC-PHARMACODYNAMIC (PKPD) STUDY OF FEBUXOSTAT IN PATIENTS WITH CHRONIC GOUT', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 47, pp. 14 - 14, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000400304400034&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2017
Simic M; Harmer AR; Agaliotis M; Nairn L; Bridgett L; March L; Votrubec M; Edmonds J; Norton R; Woodward M; Day R; Fransen M, 2016, 'CLINICAL PREDICTORS OF MEDIAL KNEE OSTEOARTHRITIS PROGRESSION OVER 2 YEARS', in OSTEOARTHRITIS AND CARTILAGE, ELSEVIER SCI LTD, Amsterdam, NETHERLANDS, Vol. 24, pp. S220 - S220, presented at World Congress of the Osteoarthritis-Research-Society-International (OARSI) on Osteoarthritis, Amsterdam, NETHERLANDS, 31 March 2016 - 03 April 2016, http://dx.doi.org/10.1016/j.joca.2016.01.424
2016
Leopoldino AO; Machado GC; Ferreira PH; Pinheiro MB; Day RO; McLachlan AJ; Hunter DJ; Ferreira ML, 2016, 'EFFICACY AND SAFETY OF PARACETAMOL COMPARED TO PLACEBO FOR KNEE AND HIP OSTEOARTHRITIS: A COCHRANE SYSTEMATIC REVIEW', in OSTEOARTHRITIS AND CARTILAGE, ELSEVIER SCI LTD, Amsterdam, NETHERLANDS, Vol. 24, pp. S44 - S44, presented at World Congress of the Osteoarthritis-Research-Society-International (OARSI) on Osteoarthritis, Amsterdam, NETHERLANDS, 31 March 2016 - 03 April 2016, http://dx.doi.org/10.1016/j.joca.2016.01.104
2016
Nguyen A; Baysari M; Kannangara D; Tariq A; Lau A; Westbrook J; Day R, 2015, 'MOBILE APPS TO ENHANCE SELF-MANAGEMENT OF GOUT: CONCORDANCE WITH MANAGEMENT GUIDELINES', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, Vol. 45, pp. 13 - 13, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354320700039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2015
Vaccher S; Kannangara D; Baysari M; Zwar N; Reath J; Williams K; Day R, 2015, 'IDENTIFYING BARRIERS TO TREATING GOUT EFFECTIVELY: A QUALITATIVE STUDY OF PATIENTS' AND GENERAL PRACTITIONERS' UNDERSTANDING AND MANAGEMENT OF GOUT', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, Vol. 45, pp. 14 - 14, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354320700041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2015
Kannangara D; Day R; Williams K; Phipps-Green A; Dalbeth N; Stamp L; Merriman T, 2015, 'THE URATE TRANSPORTER ABCG2 AND THE FRACTIONAL RENAL CLEARANCE OF URATE (FCU): CHANGING THE WAY WE THINK ABOUT HYPERURICAEMIA', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, Vol. 45, pp. 14 - 14, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354320700042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2015
Kannangara D; Graham G; Wright D; Barclay M; Stamp L; Williams K; Day R, 2015, 'TREATING GOUT PATIENTS WITH ALLOPURINOL: A CONCENTRATION- OR DOSE-RESPONSE APPROACH?', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 45, pp. 13 - 13, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354320700040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2015
Fransen M; Agaliotis M; Nairn L; Votrubec M; Bridgett L; Su S; Jan S; March L; Edmonds J; Norton R; Woodward M; Day RO, 2014, 'GLUCOSAMINE AND CHONDROMN FOR KNEE OSTEOARTHRITIS: A DOUBLE BLIND RANDOMISED CONTROLLED CLINICAL TRIAL EVALUATING SINGLE AND COMBINATION REGIMENS', in OSTEOARTHRITIS AND CARTILAGE, ELSEVIER SCI LTD, Paris, FRANCE, Vol. 22, pp. S457 - S457, presented at World Congress of the Osteoarthritis-Research-Society-International (OARSI), Paris, FRANCE, 24 April 2014 - 27 April 2014, http://dx.doi.org/10.1016/j.joca.2014.02.868
2014
Book Chapters
add
Baysari M; Chan J; Carland J; Stocker S; Moran M; Day R, 2018, 'Usability of Reports Generated by a Computerised Dose Prediction Software', in Connecting the System to Enhance the Practitioner and Consumer Experience in Healthcare, IOS Press, Netherlands, pp. 27 - 32, http://dx.doi.org/10.3233/978-1-61499-890-7-27
2018
Day R; graham GG, 2016, 'Coxibs', in Compendium of Inflammatory Diseases, Springer Basel, pp. 1 - 7, http://dx.doi.org/10.1007/978-3-0348-0620-6_22-1
2016
Graham GG; Roberts MS; Day RO; Rainsford KD, 2016, 'Pharmacokinetics and metabolism of the salicylates', in Aspirin and Related Drugs, pp. 97 - 155
2016
Day R; pile KD; graham GG; katelaris C, 2016, 'Antimalarial Drugs', in Compendium of Inflammatory Diseases, Springer Basel, Basel, pp. 97 - 101, http://dx.doi.org/10.1007/978-3-7643-8550-7
2016
Day RO; Graham GG, 2013, 'Non-steroidal anti-inflammatory drugs', in Encyclopedia of Inflammatory Diseases, edn. 6, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
2013
Day RO; Williams KM; Graham GG, 2013, 'Urate-lowering therapy: Uricosurics', in Dalbeth N; Peresa-Ruiz F; Schlesinger N (ed.), Gout, Future Medicine Ltd, pp. 174 - 188, http://dx.doi.org/10.2217/ebo.13.104
2013
Day RO; Graham GG; Williams KM, 2013, 'Propionic acid derivative drugs (Profens)', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
2013
Graham GG; Day RO, 2013, 'Salicylates', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/
2013
Pile K; Graham GG; Mahler SM; Day RO, 2011, 'Disease modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, edn. 3, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 585 - 619, http://books.google.com.au/books?id=X0deXiGtcCAC&printsec=frontcover#v=onepage&q&f=false
2011
Baysari MT; Westbrook J; Day RO, 2011, 'Medication decision-making on hospital ward-rounds', in Moen A; Andersen SK; Aarts J; Hurlen P (ed.), Studies in Health Technology and Informatics, IOS Press, Amsterdam, pp. 935 - 939, http://dx.doi.org/10.3233/978-1-60750-806-9-935
2011
Bachmeier CJ; Brooks PM; Day RO; Graham GG; Littlejohn GO; Morand E; Pile K; Williams KM, 2005, 'Disease-modifying anti-rheumatic drugs (DMARD)', in Nijkamp FJ; Parnham MJ (ed.), Principles of Immunopharmacology (2nd Ed), edn. 2nd, Birkhauser Verlag, Basel, pp. 511 - 544
2005
Day RO, 2003, 'Therapy of osteoarthritis', in Scott D; Cope A (ed.), The Year in Rheumatic Disorders 2003, edn. First, Clinical Publishibg Services Ltd, Oxford, United Kingdom, pp. 23 - 34
2003
Day RO; Quinn DI; March LM; Graham GG; Williams KM, 2000, 'Rheumatoid arthritis. New Frontiers in pathogenesis and treatment', in NSAIDs and analgesics, edn. Original, Oxford University Press, Oxford, England, pp. 307 - 328
2000
Day RO; Quinn DE; Williams KK; Handel ML; Brooks PM, 2000, 'Connective tissue and bone disorders', in Melmon and Morrelli`s clinical pharmacology: basic principles in therapeutics, edn. Original, McGrath Hill, New York, pp. 645 - 702
2000
Day RO, 2000, 'Rheumatic Disorders', in Melmon and Morrelli`s clinical pharmacology: basic principles in therapeutics, edn. Original, McGrath Hill, New York, pp. 645 - 702
2000
Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1999, 'Disease-modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, edn. 3, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 379 - 403
1999
Brady S; Day RO; Graham GG, 1999, 'Are Intra-Articular steroids as effective?', in Challenges in Rheumatoid Arthritis, edn. Original, Blackwell Science, Oxford, UK, pp. 174 - 189
1999
Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1998, 'Disease Modifying antirheumatic drugs', in Textbook of Immunopharmacology, edn. 3, Burkhauser, Basel, Switzerland, pp. 183 - 190, http://dx.doi.org/10.1097/00002281-199705000-00003
1998
Brooks PM; Day RO, 1998, 'Arthritis', in Drug Therapy in old age, edn. Original, Wiley & Sons, Chichester UK, pp. 387 - 400
1998
Day RO, 1998, 'Formulary and Guide to Prescribing (second edition)', in Formulary Guide to Prescribing (2nd Ed), edn. Original, St. Vincent's Hospital, Sydney, Australia, pp. 1 - 445
1998
Graham GG; Milligan MK; Day RO; Williams KM; Ziegler JB, 1998, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in Rainsford KD; Powanda MC (ed.), Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, Dordrecht, pp. 77 - 92, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081416000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Yeomans N; Brooks PM; Day RO, 1998, 'Non steroidal anti-inflammatory drugs and peptic ulceration', in Rheumatology (2nd Ed), edn. Original, Gower, London, pp. 27 - 28
1998
Brooks PM; Savdie E; Day RO, 1998, 'Antirheumatic drugs and renal disease', in Rheumatology (2nd Ed), edn. Original, Gower, London, pp. 28 - 29
1998
Day RO, 1998, 'SARDS', in Rheumatology (2nd Ed), edn. Original, Gower, London, pp. 8.1 - 8.10
1998
Quinn DE; Day RO, 1997, 'Guide to Clinically More Important Drug Interactions.', in Drug Safety, edn. Original, Adis International Limited, Auckland, New Zealand, pp. 1665 - 1700
1997
Graham GG; Milligan MK; Day RO; Williams KM; Zeig , 1997, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in In: `Safety and efficacy of non-prescription (OTC) analgesics, edn. Original, Kluwer Academic Publishers, Great Britain, pp. 77 - 92
1997
Day RO, 1997, 'Sulfasalazine.', in In: `The Textbook of Rheumatology`, Edition 5., edn. Original, pp. 741 - 746
1997
Reports
add
Kumar SS; Graham GG; Smith FC; Furlong TJ; Greenfield JR; Stocker SS; Carland JE; Day RO, 2017, Could metformin be used in patients with advanced chronic kidney disease?, http://dx.doi.org/10.1111/dom.12806
2017
Butterfield RJ; Barratt MJ; Ezard N; Day RO, 2016, Drug checking to improve monitoring of new psychoactive substances in Australia, AUSTRALASIAN MED PUBL CO LTD, http://dx.doi.org/10.5694/mja15.01058
2016
Roberts DM; Chau A; Day RO; Nair P, 2011, Enhanced elimination of phenorbarbital using charcoal haemorperfusion in a patient with severe poisoning, Oxford Univ Press, http://dx.doi.org/10.1093/bja/aer317, http://dx.doi.org/10.1093/bja/aer317
2011
Conference Papers
add
Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the eficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', in Antiviral Therapy, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984
2016
Manollaras K; Nolan L; Day R; Norris R; Dear R, 2016, 'EFFICACY OF SCALP COOLING AND PHARMACOKINETICS AT THE KINGHORN CANCER CENTRE, ST VINCENT'S HOSPITAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 168 - 168
2016
Baysari MT; Westbrook JI; Egan B; Day RO, 2013, 'Identification of strategies to reduce computerized alerts in an electronic prescribing system using a Delphi approach', in Lehmann CU; Ammenwerth E; Nøhr C (eds.), Studies in Health Technology and Informatics, IOS Press, Amsterdam, pp. 8 - 12, http://dx.doi.org/10.3233/978-1-61499-289-9-8
2013
Lipworth WL; Kerridge IH; Day RO, 2012, 'Evidence-based medicine, resource allocation, and the persisting problem of ethically contested outcomes', in Evidence-based medicine, resource allocation, and the persisting problem of ethically contested outcomes, New Zealand Bioethics Conference, Dunedin, New Zealand, presented at New Zealand Bioethics Conference, Dunedin, New Zealand
2012
Baysari MT; Westbrook J; Day RO, 2011, 'Ethnographic observation as a method of investigating alert fatigue', in Proceedings of the 5th International Symposium on Human Factors Engineering in Health Informatics, Tapir Academic Press, Trondheim, Norway, pp. 71 - 76, presented at 5th Human factors engineering, Trondheim, Norway, 26 August 2011 - 27 August 2011
2011
Westbrook J; Reckmann M; Li L; Day RO, 2011, 'The effectiveness of two commercial prescribing systems to reduce medication errors in hospital', in The effectiveness of two commercial prescribing systems to reduce medication errors in hospital, Annual Conference of the Australasian Association for Quality in Health Care (AAQHC), Melbourne, Australia, presented at Annual Conference of the Australasian Association for Quality in Health Care (AAQHC), Melbourne, Australia, 12 October 2011 - 14 October 2011
2011
Westbrook J; Lo C; Reckmann M; Runciman W; Braithwaite J; Day RO, 2010, 'The effectiveness of an electronic medication management system to reduce prescribing errors in hospital', in 18th Annual Health Informatics Conference, Health Informatics Society of Australia, Mebourne, pp. 1 - 8, presented at HIC 2010, 18th National Health Informatics Conference, Melbourne, Australia, 24 August 2010 - 26 August 2010, http://search.informit.com.au/documentSummary;dn=430012692310760;res=IELHEA
2010
Baysari MT; Westbrook J; Day RO, 2010, 'THE IMPACT OF COMPUTERISED DECISION SUPPORT ON SELECTING MEDICINES FOR PRESCRIPTION', in THE IMPACT OF COMPUTERISED DECISION SUPPORT ON SELECTING MEDICINES FOR PRESCRIPTION, ASCEPT Annual Scientific meeting, Melbourne, Australia, presented at ASCEPT Annual Scientific meeting, Melbourne, Australia, 28 November 2010 - 01 December 2010
2010
Franklin ME; Anderson JM; Stocker SL; Pillans PI; Williams KM; Day RO; Taylor PJ, 2009, 'Measurement of Oxypurinol Concentrations in Urine by HPLC-Tandem Mass Spectrometry', in THERAPEUTIC DRUG MONITORING, LIPPINCOTT WILLIAMS & WILKINS, Montreal, CANADA, pp. 640 - 640, presented at 11th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Montreal, CANADA, 03 October 2009 - 08 October 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270484600142&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2009
Botch B; Day RO; Vining WJ; Hixson S; Samal P; Hart D; Peterfreund A; Rath KA, 2005, 'ChemPrep: Self-paced owl preparation for general chemistry and organic chemistry', in ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, AMER CHEMICAL SOC, San Diego, CA, pp. U346 - U346, presented at 229th National Meeting of the American-Chemical-Society, San Diego, CA, 13 March 2005 - 17 March 2005
2005
Day RO; Lamont GB, 2005, 'Extended multi-objective fast messy genetic algorithm solving deception problems', in Coello CAC; Aguirre AH; Zitzler E (eds.), EVOLUTIONARY MULTI-CRITERION OPTIMIZATION, SPRINGER-VERLAG BERLIN, Guanajuato, MEXICO, pp. 296 - 310, presented at 3rd International Conference on Evolutionary Multi-Criterion Optimization (EMO 2005), Guanajuato, MEXICO, 09 March 2005 - 11 March 2005
2005
Lipani JA; Strand V; Johnson K; Woodworth T; Furst D; Singh G; Day R; Brooks P, 2001, 'A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis', in Journal of Rheumatology, pp. 1170 - 1173
2001
Day RO, 2000, 'Cox 2 Inhibitors and safety', in Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, ASCEPT: 34th Annual Scientific Meeting, Newcastle, pp. 1.12, presented at ASCEPT: 34th Annual Scientific Meeting, Newcastle
2000
Day RO; Bombardier C; Laine L; Reicin A; Ramey D; Brett C, 2000, 'Fewer Gastrointestinal Protective Agents, Procedures & Hospitalisations with Rofecoxib vs. Naproxen in the Vigor (VIOXXX GI Outcomes Research) Study', in Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, ASCEPT: 34th Annual Scientific Meeting, Newcastle, pp. 6.35, presented at ASCEPT: 34th Annual Scientific Meeting, Newcastle
2000
Day RO, 1999, 'Drug interactions with methadone: Pharmacokinetics', in Workshop on the Induction and Stabilisation of patients onto methadone, Workshop on the Induction and Stabilisation of patients onto methadone, Adelaide, Sth Aust, presented at Workshop on the Induction and Stabilisation of patients onto methadone, Adelaide, Sth Aust, 28 January 1999 - 29 January 1999
1999
Day RO; Mclachlan AJ; Williams KM, 1998, 'Population pharmacokinetics (PK) and pharmacodynamics (PD) of tenoxicam (TN) in patients with rheumatoid arthritis (RA)', in Clinical Pharmacology and Therapeutics, Mosby, St Louis, MO, USA, pp. 168, presented at Clinical and Pharmacology Therapeutics, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000072420300125&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Williams KM; Mclachlan AJ; Day RO; Pritchard A, 1998, 'Comparative pharmacokinetics of hepatitis B immuno-globulin after intramuscular administration in healthy subjects', in Naunyn - Schmiedebergs Archives of Pharmacology, Springer, New York, NY, USA, pp. 285, presented at Archives of Pharmacology 358, Munich, Germany, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000075207701061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
1998
Carmody JJ; Walker JS; Sheather-Reid R; Vial JH; Day RO, 1998, 'Non steroidal anti-inflammatory drugs (NSAIDS) in rheumatoid and osteoarthritis: support for the concept of `responders` and `non-responders`', in Naunyn - Schmiedebergs Archives of Pharmacology, Springer, New York, NY, USA, pp. 15, presented at Archives of Pharmacology 358, Munich, Germany
1998
Weekes LM; Brooks C; Day RO, 1998, 'Describing the performance of pharmacy and therapeutics committees', in Clinical Pharmacology and Therapeutics, Mosby, St Louis, MO, USA, pp. 179, presented at Clinical and Pharmacology Therapeutics
1998
Ziegler JB; Graham GG; Day RO; Williams KM; Milligan MK, 1997, 'THERAPEUTIC CONSIDERATIONS FROM PHARMACOKINETICS AND METABOLISM: IBUPROFEN AND PARACETAMOL.', in Safety and Efficacy of non-prescription (OTC) analgesics and NSAIDs, Kluwer Academic Publishers, Dordrecht, presented at Safety and Efficacy of non-prescription analgesics and NSAIDS, San Francisco, California USA, 17 March 1997 -
1997
Conference Posters
add
Chroinin DN; Xiao D; Sandhu A; Brazel C; Farnham N; Neto HM; Perram J; Roach TS; Sutherland E; Day R; Beveridge A, 2015, 'Potentially inappropriate medications (PIMS) in older hospital in-patients: prevalence at admission and discharge, and contribution to hospital admission', Vol. 34, pp. 67 - 67, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354463000124&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2015
Vaccher S; Kannangara D; Baysari M; Zwar N; Reath J; Williams K; Day R, 2014, 'Barriers to care in gout: A qualitative study of patients’ and prescribers’ understanding and management', Melbourne, Australia, presented at ASCEPT Scientific Meeting, Melbourne, Australia, 07 December 2014
2014
Matthews GV; Kaur A; Ray JE; Graham GG; Egan B; Williams KM; Day RO, 2013, 'USE OF A POPULATION PHARMACOKINETIC MODEL TO PREDICT WEEK 4 RIBAVIRIN LEVELS FROM EARLY CONCENTRATIONS', Amsterdam, NETHERLANDS, Vol. 58, pp. S357 - S357, presented at International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, NETHERLANDS, 24 April 2013 - 28 April 2013, http://dx.doi.org/10.1016/S0168-8278(13)60872-7
2013
Walker JS; Day RO; Wessell H; Arroyo J, 1990, 'Validation of a human model of experimental pain for testing pharmacodynamics of non-steroidal anti-inflammatory drugs', Vol. 183, pp. 1036, http://dx.doi.org/10.1016/0014-2999(90)92893-N
1990
Day RO; Walker JS; Seideman P; Knihinicki RD; Williams K, 1990, 'A human model for evaluation of non-steroidal anti-inflammatory drug (NSAID) distribution into extracellular fluid', Vol. 183, pp. 1034, http://dx.doi.org/10.1016/0014-2999(90)92891-L
1990
Conference Presentations
add
Merriman T; Topless R; Day R; Kannangara D; Williams K; Bradbury L; Brown M; Harrison A; Hill C; Jones G; Lester S; Littlejohn G; Rischmueller M; Shenstone B; Smith M; Andres M; Bardin T; Doherty M; Janssen M; Jansen T; Joosten L; Perez-Ruiz F; Radstake T; Riches P; Roddy E; Tausche A-K; Stamp L; Dalbeth N; Liote F; So A; Rasheed H, 2014, 'ASSOCIATION OF THE TOLL-LIKE RECEPTOR 4 (TLR4) GENE WITH GOUT', Vol. 73, pp. 354 - 354, presented at 15th Annual European Congress of Rheumatology (EULAR), Paris, FRANCE, 11 June 2014 - 14 June 2014, http://dx.doi.org/10.1136/annrheumdis-2014-eular.4781
2014
CHAMPION GD; BIERI D; BROWNE CD; CAIRNS D; DAY RO; GRAHAM GG; HARRIS G; SAMBROOK PN, 1983, 'DETERMINATION OF RESPONSE OF INDIVIDUAL PATIENTS WITH RHEUMATOID-ARTHRITIS TO AURANOFIN', Vol. 10, pp. 674 - 674, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1983RW31100055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1983
HILLS LJ; BIERI D; CHAMPION GD; DAY RO; GRAHAM GG; HASKI A; PAULL PD, 1977, 'STATISTICAL PROCEDURES IN ANALYSIS OF AN ANALGESIC STUDY', Vol. 7, pp. 458 - 459, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1977DS42200078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1977
BIERI D; CHAMPION GD; CORRIGAN AB; CROFT R; DAY RO; GRAHAM GG; HILLS L; TATHAM H, 1977, 'BIOAVAILABILITY, GASTROINTESTINAL MICROBLEEDING AND SIDE-EFFECTS OF 4 ASPIRIN FORMULATIONS IN SUBJECTS WITH RHEUMATOID-ARTHRITIS', Vol. 7, pp. 458 - 458, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1977DS42200077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1977
BIERI D; CHAMPION GD; DAY RO; GRAHAM GG; HASKI AL, 1977, 'MEASUREMENT OF SUBJECTIVE PARAMETERS OF RHEUMATOID-ARTHRITIS - DEVELOPMENT OF AN INDEX OF FUNCTION', Vol. 7, pp. 92 - 92, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1977DH49400031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1977
GRAHAM GG; CHAMPION GD; DAY RO, 1977, 'INFLUENCE OF CORTICOSTEROIDS ON METABOLISM AND PLASMA CONCENTRATIONS OF SALICYLATE', Vol. 7, pp. 91 - 91, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1977DH49400028&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1977
CHAMPION GD; DAY RO; PAULL PD; GRAHAM GG; OWEN MS; HASKI AL, 1975, 'CLINICAL PHARMACOLOGY AND EFFICACY OF BENORYLATE IN PATIENTS WITH RHEUMATOID-ARTHRITIS', Vol. 5, pp. 501 - 501, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1975AU07300093&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1975
Champion GD; Day RO; Paull PD, 1975, 'Clinical pharmacology and efficacy of benorylate in patients with rheumatoid arthritis', Vol. 2, pp. 416 - 417
1975
1975